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ABSTRACT 
The protein, RDE-4 in C. elegans, served as a model for studying how double 
stranded RNA binding proteins that bind to dsRNA molecules are critical for RNAi 
cellular processes. NMR spectroscopy confirms that the RDE-4 construct has 
characteristic protein domains that bind to. dsRNA and that RNA binding causes a 
significant global change of the protein structure. SAXS analysis indicates that the 
two binding domains in the RDE-4 protein do not interact with one another, but 
instead forms a continuous interface onto which long target dsRNA can bind. Gel 
shift assay experiments reveal that multiple RDE-4 molecules bind to a non-
sequence specific RNA substrate with positive cooperativity. RNA binding occurs 
with micromolar affinity and a second binding event occurs with millimolar affinity. 
The binding of E. coli dihydrofolate reductase (DHFR) to inhibitors methotrexate 
(MTX) and 1,4-Bis-{[ N-(1-imino-1-guanidino-methyl)] sulfanylmethyl}-3 ,6-
dimethyl-benzene (inhibitor 1) has been studied to investigate the dynamics 
involved in the catalytic mechanism of DHFR. NMR relaxation methods show that in 
the presence of inhibitor 1, the catalytic domain of DHFR binds 1 in the substrate-
binding pocket and an occluded conformation is assumed. In both the DHFR:NADPH 
and DHFR:NADPH:1 complexes, motion is exhibited on the microsecond-millisecond 
timescale. The heat capacity change of DHFR upon binding to 1 and MTX are 43 ± 
10 cal/mol-K and -120 ± 109 cal/mol-K respectively. Differences in LlCp of DHFR 
11 
binding to inhibitor 1 compared to that of MTX indicate that the mode of binding to 
1 is different from what is observed in the crystal structure of the complex. 
An affinity electrophoresis method to screen for RNA-small molecule ligand 
interactions has been developed. This method is made quantifiable by cross-linking 
the ligand into the gel matrix and gauging binding by RNA mobility. The utility of 
this method is demonstrated using the known interaction between different 
aminoglycoside ligands with the E. coli ribosomal A-site RNA and with an RNA 
molecule containing a C-C mismatch. Average apparent dissociation constants are 
determined. This method allows an easy quantitative comparison between different 
nucleic acid molecules for a small molecule ligand. 
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CHAPTER! 
INTRODUCTION 
1 
1.0 INTRODUCTION 
1.1 BIOMOLECULAR INTERACTIONS 
Biomolecular interactions play a fundamental role in the majority of key 
biochemical processes. Biomolecules can form a variety of interactions including 
protein-protein, protein-nucleic acid, protein-small molecule, and nucleic acid-small 
molecule interactions. To gain a better understanding of the array of interactions, 
and more specifically the relationship between biomolecular interactions and 
cellular processes, it is important to investigate the mechanisms involved and the 
effects of these interactions. This knowledge gives rise to the function of 
biomolecules, which can lead to significant advances in diagnostic applications and 
in the treatment of diseases. 
This chapter provides background information on the three projects 
presented in this dissertation as well as the details of the techniques used in each 
project. 
1.2 PROTEIN-RNA INTERACTIONS 
The recognition of ribonucleic acid (RNA) molecules by proteins is critical for 
understanding cellular processes such as gene expression, RNA processing, and viral 
replication. Since RNA molecules have fairly diverse structures, proteins that 
interact with RNA must be able to recognize an assortment of RNA [1, 2]. The non-
2 
canonical Watson-Crick base pairing of single-stranded like structures of RNA 
allows for a range of geometries that facilitates greater hydrogen-bonding ability 
and base stacking capabilities. Even though the size, shape, and general binding 
interactions may vastly differ between RNA molecules, proteins can conform tight 
binding pockets for specific RNA with few contact points upon complex formation 
[3]. The structures found in RNA molecules are much more diverse than those of 
deoxyribonucleic (DNA) molecules, suggesting that protein-RNA interactions can be 
quite different than protein-DNA interactions [3, 4]. 
The three dimensional structure of an RNA molecule is helpful for 
understanding how the RNA molecule docks onto a protein molecule. If the three-
dimensional structure of an RNA molecule is unknown, considering the type of RNA 
of interest can often allow for conformational predictions. Most often, RNA 
molecules that have extensive structures such as tRNA and rRNA are rigid whereas 
other RNA such as mRNA, non-protein coding RNA (ncRNA), and small nuclear RNA, 
(snRNA) are fairly flexible [1, 3]. 
Proteins that bind RNA have characteristic domains containing amino acid 
sequences that allow for RNA interactions. Comparing the similarity of domain 
sequences to the sequences of proteins with known RNA binding domains often 
makes the prediction of RNA-binding proteins possible, although this is not the only 
condition for which proteins need for RNA binding to occur. Information about the 
RNA-binding interface on the surfaces of proteins provides a means for making 
binding predictions. An easy approach to making predictions about protein-RNA 
3 
complex formation is to determine the electrostatic potential of the surface of the 
given protein and evaluate the opportunity of the protein binding RNA [3]. Since the 
RNA molecule carries a negative charge due to the phosphate backbone, it is logical 
to assume that the RNA interface on the protein surface has a positive electrostatic 
potential. It must be noted that the pH and ionic strength of the solvent used can 
alter the electrostatic potential. 
RNA interfaces on protein surfaces are reported to contain preferred amino 
acids residues for binding. To compliment the negative charge of RNA, amino acids 
with positive charges such as arginine (Arg) and lysine (Lys) frequently appear in 
regions of the protein sequence that suggests an RNA interface. In addition, RNA 
molecules favour van der Waal contacts with amino acids that have aromatic side-
chains that allow for stacking interactions with the RNA bases. Furthermore, the 
location of amino acid residues at the interface is spatially located so that its 
neighbour in the tertiary protein structure is also part of the same interface [3]. 
1.2.1. Double Stranded RNA-Binding Proteins (dsRBPs) 
Proteins with conserved double stranded RNA-binding domains (dsRBDs) 
are a growing protein class found in eukaryotes, prokaryotes, and viral products 
that facilitate the interaction with double stranded RNA (dsRNA) [5]. These double 
stranded RNA binding proteins ( dsRBPs) have been reported to have critical and 
diverse roles in cellular processes including the regulation of gene expression, RNA 
editing, RNA transport, RNA processing, and host defense in biological processes [5]. 
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Examples include S. cerevisiae RNase III (rntlp) that cleaves RNA substrates 
containing hairpins with an A/uGNN tetraloop cap (Figure 1.1) [6] and protein 
kinase PKR that is involved in dsRNA signaling, RNA interference (RNAi) and host 
defense against viral infection [5]. 
Figure 1.1: Solution structure of double stranded RNA binding domain of S. 
cerevisiae RNase III (rntlp) (green) with the terminal RNA hairpin of snr47 
precursor (PDB ID: 2LUP) [6]. 
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The dsRBD is a small protein domain consisting of at least one a~~~a motif 
of 65-70 amino acids. The discovery of dsRBDs as dsRNA binding domains was first 
recognized in 1992 as a conserved functional domain based on sequence similarity 
matches between the proteins Staufen in Drosophila, human TAR-RNA binding 
protein (TRBP), and Xenopus leavis RNA binding protein A (XlrbpA), along with 
characterization of dsRBDs in human protein kinase (PKR) and human TRBP [7]. 
The dsRBD domain is one of the most abundant RNA binding domains found in 
cellular systems aside from the RNA recognition motif (RRM) that is known to 
mostly bind single-stranded RNA (ssRNA). It is important to note that dsRNA 
binding is not limited to dsRBDs, rather other domains known to bind dsRNA 
include zinc fingers and SAM domains, and RRM domains [7]. The solution NMR 
structures of E. coli RNase III dsRBD and the third dsRBD of Drosophila Staufen were 
the first three-dimensional structures of dsRBDs to be solved [7]. 
Interestingly, proteins with dsRBDs have been found to interact with short 
strands of A-form helix dsRNA that are 11-16 base pairs of usually nonspecific 
nucleotide sequences [5]. Proteins that bind dsRNA have been found to bind 
sequence specific dsRNA targets in vivo, however, rather than being sequence 
specific, binding of dsRBDs to dsRNA is commonly believed to be dependent on the 
shape of dsRNA [7]. One reason being that A-form helix dsRNA differs form classic 
B-form dsDNA in that the major groove is shallow and broad and the minor groove 
is deep and narrow, allowing dsRBPs to bind nonspecifically to dsRNAs. The lack of 
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nucleotide specificity suggests that other helper proteins are needed to assists with 
target recognition [5]. 
1.3 PROTEIN-SMALL MOLECULE INTERACTIONS 
The interaction of small molecules with proteins is a central 
component of many diverse biological processes. Such interactions are often seen in 
regulatory systems and catalytic cycles. One of the most recognized instances of a 
small molecule binding with a protein is the interaction of an 02 molecule with 
hemoglobin to transport oxygen from the respiratory systems to the rest of the body 
(Figure 1.2) [8, 9]. The function of the small molecule moiety is highly selective for 
the target protein. For this reason, the small molecules are often used as bait for 
studying protein binding where the selectivity functional group of the molecule can 
be exploited to explore the complexity of binding modes and ligand orientation 
preferences known as "molecular docking" [10, 11]. Currently available methods for 
studying ligand-protein interactions, and more specifically molecular docking, 
largely involve computer algorithms as a virtual screen tool [11]. In doing so, it is 
possible to quickly and efficiently classify the binding of a vast set of small 
molecules with a target protein, which is extremely useful to the pharmaceutical 
industry [10, 11]. When the small molecule that is used ~s bait is a pharmaceutical 
compound, screening processes can lead to the discovery of drug targets [10]. For 
drug target discovery, it is important that other functionalities can be positioned on 
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parts of the small molecule, especially when a structure-activity relationship is 
unclear or unknown [1 O]. 
Figure 1.2: Three-dimensional structure of hemoglobin (blue) (PDB ID: lGZX) in 
complex with 4 oxygen molecules (pink) [9]. 
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Design strategies used for profiling small molecule-protein interactions often 
involve bi-functional probes that have an equilibrium-driven affinity with the target 
protein. One such strategy is the affinity pull-down approach that involves linking 
the target protein to a solid phase and subsequently allowing the probe to interact 
with the linked protein by passing the probe over the solid phase. The result is a 
low-affinity reversible interaction between the probe and target protein, which can 
be desirable in certain cases, however, unspecific binding proteins and buffer 
conditions may affect the recovery yield of the proteins of interest [10]. This 
strategy has been employed successfully to isolate various kinases in eukaryotic 
lysate by using kinase inhibitor beads [12, 13]. Activity based protein profiling 
(ABPP) is another type of probe strategy that instead uses small molecules that 
contain chemical groups that can directly react with amino acids in an enzyme 
active site by creating strong covalent bonds, thereby avoiding the problem of losing 
the small molecule-protein interaction during subsequent procedural steps [10]. 
ABPP is a common approach used for protein family profiling such as the cysteine 
hydrolase family of hydrolytic enzymes [14, 15]. In the strategy of Capture 
Compound Mass Spectrometry (CCMS), the small molecule probe is comprised of a 
central atom with three protruding functional units capable to selectively binding to 
target proteins in an equilibrium-driven manner. The established equilibrium is 
then "frozen" by a photo-activation process that results in a covalent bond crosslink 
that is strong enough to withstand further processing steps [10]. CCMS has been 
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used to select for protein families such as camp-.binding protein [16] and GTPases 
[17]. 
The applications of small molecule-protein interaction profiling serves as a 
powerful tool as it benefits the field of drug discovery for treating diseases [18] and 
extends to the identification of natural products [19]. There is no doubt that 
understanding small molecules-protein interactions is necessary for uncovering the 
complexity of many biological processes. 
1.4 RNA-SMALL MOLECULE INTERACTIONS 
As the diverse responsibilities of RNA in biological pathways are becoming 
more evident, small molecules that selectively bind to RNA are also becoming more 
important for gaining insight into the many roles that RNA undertake, such 
transcriptional and translation regulation [20, 21], catalysis [22], and protein 
function [23]. Although protein targets form the basis of drug discovery, RNA 
targets are increasingly viewed as an alternative method for developing treatments 
for diseases [24]. Like DNA and proteins, RNA has many attractive features that 
allows for interaction with a small molecule target. However, RNA molecules are 
capable of adopting many complex three-dimensional structures because 
mismatched or unpaired bases in the nucleotide sequence can easily disrupt the 
regular A-form helix normally seen in nucleic acids [24]. It is this structural 
diversity that enables RNA to facilitate a wide range of biological pathways. It is not 
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surprising that RNA possesses the potential for therapeutic-based applications with 
antibacterial, antiviral and mRNA being the three most common RNA targets. For 
example, studies have shown that certain ribosomal RNA (rRNA) can bind with 
aminoglycoside antibiotics to initiate an antibacterial effect [25]. Also, several 
riboswitch RNA can form a complex with a small molecule metabolite to regulate 
translation (Figure 1.3) and even display antibacterial properties upon binding 
when targeted by an inhibitor of the normal riboswitch-ligand interaction [26, 27]. 
Figure 1.3: The SAM-I Riboswitch in complex with S-adenosylmethionine (pink) 
(PDB ID: 2YGH) [27]. 
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The manner in which an RNA molecule is folded can indicate the possibility 
of an interaction with a small molecule. The structural hierarchy of RNA is such that 
the primary nucleotide sequence determines the secondary structure that 
subsequently dictates the tertiary structure. Since RNA molecules are single 
stranded, they require a definite tertiary structure in order to be functional. This 
scaffold is reinforced by a network of hydrogen bonding to create secondary 
structure elements such as hairpin loops, internal loops, bulges, and duplexes [2, 
28]. Ligand-binding sites often occur at a single secondary structure element and 
secondary structures often provide pockets to secure small molecule interactions 
[24]. 
Selectively targeting RNA with small molecules is made possible with 
screening methods and RNA binding assays are available to determine the strength 
of binding affinity [24]. However, RNA biochemistry is still relatively new and there 
is a lot to be uncovered. An increase in RNA-small molecule research and advanced 
screening techniques are required to make detailed characterization of RNA-small 
molecule interactions achievable and to encourage the study of these complexes as a 
viable avenue for drug discovery. 
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1.5 RNA INTERFERENCE 
This section provides an overview on the topic of RNA interference as it 
relates to the research project outlined in Chapter 2. 
The RNA-related discovery that has gained the most widespread recognition 
and use is that of RNA interference (RNAi), a process that occurs innately in cells as 
a sequence dependent cellular response to RNA [29-31]. The role of double stranded 
RNA (dsRNA) in gene regulation through RNAi has defined a new biological role for 
RNA that has generated much interest since its discovery. RNAi is conserved in all 
eukaryotes and is involved in many diverse biological events including embryo 
development, viral defense and cancer progression. The ability of RNAi to silence 
the activity of specific genes using short ( --22 base pair) RNA molecules has 
directed the use of RNAi to being a therapeutic modality and has also found 
applications in proteomics research [32-35]. The significance of the discovery of 
RNAi was recognized in 2006 by the awarding of the Nobel Prize in Physiology or 
Medicine to Craig Mello and Andrew Fire for their work on RNAi that was published 
in 1998 [29]. 
RNAi is believed to have evolved as a cellular defense mechanism against 
foreign intruders such as RNA viruses [36]. When viral RNA replicate, it temporarily 
exists as a double strand that is processed into short dsRNA to trigger the cascading 
events of RNAi. The virus' genes are effectively silenced and infection by the virus is 
avoided. RNAi may have also evolved to prevent the mobilization of transposable 
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genetic elements called transpoons [37]. Damage by transpoons is a result of the 
ability of these genetic elements to translocate on several areas on a genome, 
causing genetic mutations that can lead to diseases such as cancer. Transpoons, like 
RNA viruses, can adopt a double stranded RNA form that, when processed to short 
dsRNA, initiates RNAi to halt potentially damaging translocation. 
The different classes of short RNA molecules that trigger RNAi are expanding 
steadily. These groups include micro RNA (miRNA), small interfering RNA (siRNA), 
repeat-associated siRNAs (rasiRNA), endogenous siRNA (endo-siRNA), and Piwi-
interacting RNA (piRNA) [34, 38]. These small noncoding RNA molecules work by 
suppressing the expression of genes targeted by their nucleotide sequence. These 
classes of short RNA molecules are differentiated by the origin of the trigger RNA 
that initiates RNAi and the diverse biological roles they play. The trigger RNA can 
have either an endogenous or exogenous origin (Figure 1.4). 
14 
dsRNA 
pn~-miR'NA 
NUCLEUS 
1nhlib~tfo.n of 
RNA .synthes;is ' 
Figure 1.4: The processing pathways of miRNA and siRNA that are involved in 
RNAi. Short RNAs are differentiated by the origin of the trigger RNA. Adapted from 
[39]. 
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Processing of siRNAs from endogenous or exogenous dsRNA precursors that 
are composed of perfectly base paired RNA results in short RNA strands that can 
bind to a complimentary sequence of target mRNA, causing the mRNA to be targeted 
for degradation. Mature miRNAs are structurally similar to siRNAs, however 
miRNAs must undergo extensive post-transcriptional modifications before entering 
the silencing pathway [ 40]. The miRNA originates as a long single stranded primary 
transcript that is transcribed by RNA polymerase II from a much longer RNA coding 
gene. This primary transcript, known as pri-miRNA, is processed in the nucleus to a 
70-nucleotide stem loop structure called pre-miRNA by the processor complex. This 
complex consists of an RNase III endonuclease named Drosha and the essential 
dsRNA-binding protein cofactor called DGCR8 in humans or Pasha in invertebrates. 
The pre-miRNA is exported to the cytoplasm where Dicer, a second RNase III 
endonuclease, processes the dsRNA segment of the pre-miRNA to a short double 
strand miRNA duplex. Finally, an ATP-dependent helicase unwinds the short double 
strand miRNA duplex into two strands of mature single-stranded mi RNA. One of the 
two strands, known as the guide strand or antisense strand, is incorporated into the 
RNA induced silencing complex (RISC) and then annealed to the target mRNA to 
perform regulatory functions. Although structurally similar to siRNAs, miRNAs 
regulate gene expression by binding to sequences in the 3' untranslated region 
(UTR) [ 41] of mRNAs by way of partial base pairing in mammals and perfect base 
pairing in plants, enabling the miRNA to regulate many mRNA with similar 
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sequences [34, 42, 43]. Binding of the 3' UTR mRNA leads to mRNA degradation or 
translational suppression. 
Over 300 miRNAs are recognized in humans, however the exact function of 
the members of this group of RNA is still largely unclear [34]. Endogenous miRNAs 
are most important in translational repression, cellular developmental regulation 
and stem cell maintenance [44]. Studies have also shown that miRNA influences 
viral replication in mammals by having either a viral or anti-viral response [45]. 
Some viruses such as the Epstein-Barr virus (a member of the human Herpesvirus) 
and the Adenovirus, have been shown to encode mi RN As [ 46]. In the case of the 
Polyomavirus, Simian Virus 40 (SV 40), the virus is able to potentially escape the 
immune response of the cytotoxic T cells by having its miRNA hybridize to a 
complimentary transcript encoding large T antigen [47]. Cellular miRNA can also 
have an alternate role that effectively inhibits or limits the replication of 
retroviruses. For example, replication of the Primate Foamy Virus type 1 (PFV-1), a 
complex retrovirus similar to Human Immunodeficiency Virus (HIV), is inhibited by 
cellular miR-32 that binds to the viral mRNAs [48]. 
In many organisms, including humans, miRNAs directly function as 
oncogenes or tumor supressors, with more than 50% of miRNA genes located in 
cancer-associated regions. Many miRNAs are directly implicated in human cancers, 
including lung, breast, brain, liver, colon, and bone marrow. Evidence for the 
contribution of miRNAs in cancers was initially reported in a 2002 molecular study 
characterizing the deletion of 13q14 in human chronic lymphocytic leukemia (CLL), 
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which is known to be the most prevalent form of adult leukemia in North America 
[ 49]. In cancers, overexpressed mi RN As such as mir-17-92 acts as oncogenes and 
negatively regulates genes that control tumor suppression, cell differentiation, or 
apoptosis [SO]. The miRNAs with oncogenic roles are usually expressed at 
remarkably higher levels in cancer tissues compared to normal tissues. 
Underexpressed miRNAs can function as tumor suppressor genes that regulate 
oncogenes, cell differentiation, or apoptosis [51]. These mi RN As have decreased 
expression in cancerous cells and often inhibit the expression of a target oncogene 
by binding to the 3' UTR of the oncogene's mRNA to repress translation. For 
example, the let-7 miRNA negatively regulates expression of the RAS oncogene. In 
many human cancers, let-7 is often downregulated or deleted. Studies have reported 
that restoration of low levels of the let-7 miRNA in cancerous lung cells by the 
introduction of increased let-7 can effectively repress cell proliferation [52]. This 
ability to prevent tumorgenesis makes miRNAs, such as let-7, an appealing potential 
therapeutic [52, 53]. Depending on the type of cancer, miRNAs may have different 
expression profiles in cancerous cells compared with normal cells [54]. This 
suggests that in some instances, the same miRNA can function both as oncogenes or 
tumor suppressor depending on the type of cancer. Although the classification of 
miRNAs can be made by techniques such as expression profiling [54], better 
understanding of how miRNAs function in human oncogenesis on a molecular basis 
can potentially lead to early prognosis and possible treatments. 
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Despite their differences in origin, short RNA molecules are generated by the 
same general mechanism (Figure 1.4). In the initial stages of RNAi, the Dicer 
complex processes the trigger dsRNA into short ( ,..,zz base pair) interfering dsRNA 
(siRNA) molecules that is then incorporated into the RNA-induced silencing 
complex (RISC). Guided by the siRNA, the RISC then either degrades the mRNA 
molecules or represses translation based on the complementarity of the target 
mRNA to the siRNA [SS]. 
1.6 PROTEIN NMR SPECTROSCOPY 
Nuclear Magnetic Resonance (NMR) spectroscopy is one of the few methods 
available for studying the three-dimensional structures of proteins at an atomic 
level and is still the only method for determining high-resolution three-dimensional 
protein structures in the solution state. Low-resolution protein structures are often 
achieved by the technique of small angle X-ray scattering (SAXS). The constitution 
of proteins is based on the unique connection of amino acids comprised of 
hydrogen, nitrogen, and carbon nuclei, among others, that can be detected by NMR 
spectroscopy when the nuclear spins go from its ground state to an excited state. 
This energy transition can be achieved by applying a static external magnetic field 
(Bo), a requirement that makes NMR spectroscopy a very attractive technique 
because it allows for a broad range of transition frequencies by simply using an 
oscillatory field (81) of radio-frequency (RF) electromagnetic radiation [S6]. 
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The energies associated with this type of two-energy level system results 
from the interaction of the external magnetic field and a nuclear magnetic dipole 
moment (µ) that arises from the spin angular momentum (S) of the nucleus. Nuclei 
that have a spin angular momentum include all nuclei with an odd mass number 
such as lH, 13C, and 1SN because they have an unpaired proton. Nuclei with an even 
mass number and an odd charge such as 2H and 14N also have a spin angular 
momentum [57]. 
The spin angular momentum is a vector property that characterizes the 
nucleus as a spinning particle that produces a magnetic field described by a 
proportional magnetic dipole moment vector (Figure 1.5) [S 7]. In the absence of a 
magnetic field, all possible orientations of the magnetic dipole of the nuclear spins 
are present. However, the spin orientation can be made uniform when placed in a 
static magnetic field so that spins re-align to the direction of the z-axis defined by 
the magnetic field [57]. Note that the actual magnetic field felt by the nucleus is 
most often somewhat modified by surrounding electrons that shield the nucleus. 
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Figure 1.5: Orientation of the nuclear magnetic dipoles (µ) in the presence of a 
static magnetic field (Bo) along the z-axis. On average one half of the nuclear 
magnetic dipoles are pointed upward as 1h (low energy spin state) and the other 
half are pointed downward as -1h (high energy spin state). Since the magnet is 
spinning, the angular momentum is conserved and does not simply align with Bo. 
Instead, the nuclear magnetic dipoles precess around the magnetic field. Adapted 
from [57]. 
21 
When a nucleus is placed in an external magnetic field, Bo, the nucleus acts as 
a rotating particle causing the magnetic field of the nuclei to precess around the axis 
of Bo. In actuality, all of the spins in a sample precess randomly around Bo at their 
specific Larmor frequency; however, slightly more of the nuclei are in the lower 
energy 1h spin state (Figure 1.6 A). This is called Larmor precession [56, 58]. The 
frequency property associated with this precession is proportional to the strength 
of the external magnetic field, meaning that higher frequencies are obtained with a 
stronger external magnetic field. To observe the magnetic moment of precessing 
nuclei, the nuclear magnetization must be made perpendicular to Bo, which can be 
achieved by applying a radio frequency pulse (B1) that is the same frequency as the 
Larmor frequency and perpendicular to Bo [57]. In other words, the bulk nuclear 
magnetization of the sample is tipped from the z-axis to the x-axis (Figure 1.6 B). 
After the pulse is applied, the rotating magnetic field induces an electric current that 
is measured by receiver coils in the circuit and digitized. Over time, the induced 
current declines because the perpendicular nuclear magnetization becomes out of 
phase and the magnetization returns the direction of the Bo axis. This decay rate is 
referred to as the free induction decay, FID, and is a function of time. Converting the 
time domain to a frequency domain by Fourier transformation allows the FID to be 
observed as an NMR spectrum [58]. 
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Figure 1.6: A) Collection of nuclear magnetic dipoles precessing around the axis of 
Bo. B) The bulk magnetization tipped from the z-axis to the x-axis, causing the bulk 
magnetization to remain in the z-x plane during the entire period of the pulse. 
Adapted from [5 7]. 
To study proteins using NMR, proteins are typically uniformly isotopically 
labeled with 15N and 13C nuclei by recombinant expression in minimal media that 
contain 15N ammonium sulfate or 1SN ammonium chloride as the sole nitrogen 
source and 13C glucose as the sole carbon source. For larger proteins, complete or 
partial 2H labeling in D20 or D20 /H20 mixture, a process called deuteration, may 
also be necessary. The downside of isotopically labeling is that it can be fairly 
expensive [59]. However, in doing so, various multinuclear experiments can be 
employed that allow for efficient magnetization transfer via }-coupling between 
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nuclei in the same or adjacent amino acid and thereby correlating the associated 
chemical shifts [60] (Figure 1.7). 
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Figure 1.7: }-coupling constants between nuclei in an amino acid that allows for 
efficient magnetization transfer during multinuclear NMR experiments. Adapted 
from [57, 61]. 
Typically, structure determination of protein in the size range of 5-25 kDa is 
relatively facile, unless there are issues of aggregation and reduced solubility. With 
larger proteins, magnetization transfer between nuclei is decreased due to rapid 
signal decay by dipolar interactions and chemical anisotropy. Due to the increased 
protein size, molecular tumbling reduces the signal-to-noise (S/N) ratio in three-
dimensional experiments by increasing magnetic field fluctuations that are a 
function of nuclear gyromagnetic ratios in the spin system [62]. Linewidth is also 
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increased by poor protein relaxation, which causes a reduction in resolution. For 
these reasons, structure determination by NMR is limited to proteins with molecular 
weights less than about 40-60 kDa [58]. 
1.7 TRIPLE RESONANCE EXPERIMENTS 
Detailed information about protein backbone resonances can be obtained by 
performing triple resonance experiments that involve 15N, 13C and 1H spins to 
generate three-dimensional spectra. This method is highly reliable, sensitive, 
simple to apply, and imperative for assigning resonances that are used to determine 
a protein's structure with confidence, especially when a protein is fairly large [57]. 
Large proteins (> 150 residues) often produce poor quality spectra because 
tumbling is slow due to the size of the protein. In such cases, multiple 
complimentary types of triple resonance experiments are needed to obtain 
sufficient information for making full assignments [63]. For very large proteins (> 
250 resides), deuteration is usually necessary [57]. 
A large number of triple resonance pulse sequences have been created that 
allows for magnetization transfer between nuclei [63]. The magnetization pathway 
is reflected in the nomenclature for these experiments where the nuclei are listed by 
the frequency order in the pulse sequence. Spins are enclosed in parentheses when 
magnetization passes through spins with no frequency labeling. Amide protons are 
listed in the experiment name first when magnetization begins on that proton and 
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returns on the same proton for detection. This type of transfer is known as an 'out-
and-back' experiment [63]. 
Complete sequential connectivities can be obtained using triple resonance 
experiments. To begin this strategy, the amide group (NHHN) chemical shifts of a 
spin system are correlated with the inter- and intra- residues chemical shifts of the 
backbone or sidechain atoms. The term matching atom is often referred to the atom 
that has shared correlations with an atom or atoms in it's own spin system and the 
spin system of a preceding residue [57]. For example, in the HNCA experiment, the 
amide nitrogen is coupled to the alpha carbon (Ca) in the residue (i) in which it is 
involved as well as to the Ca in the preceding residue (i-1) (Figure 1.8). Therefore, 
in this experiment Ca is the matching atom since both of these Ca nuclei are 
observed in the spectrum, with the Ca in its own residue showing up as a more 
intense peak due to a direct N-Ca coupling [64]. 
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Figure 1.8: Correlations in an HNCA triple resonance experiment. In this 
experiment, Ca is the matching atom and both Ca nuclei appear in the spectrum. 
Adapted from [57]. 
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Once the matching atom is identified, the amide of the residue i can be used 
to dete.rmine the frequency of the amide of the preceding residue. This process can 
be continued until all the backbone connectivities are obtained. Although this 
appears to be a very simple process, ambiguities can arise if a matching atom has a 
shift that is not easily distinguished in the protein sequence. Triple resonance 
experiments commonly used that are sufficient for protein structure determination 
include the HNCA, HNCACB, CBCACONH, HNCA, HNCACO and HNCO experiments 
(Figure 1.9) [57, 63]. 
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Figure 1.9: Correlations in common triple resonance experiments. Adapted from 
[57]. 
27 
1.8 NMR RELAXATION IN PROTEINS 
Following irradiation, the nuclear spins return to equilibrium along the z-axis 
of the external magnetic field in a process called relaxation. The resulting relaxation 
process is significant because it is largely responsible for the signal detected from 
the observed nuclei. In proteins, the relaxation rate constants for nuclei takes into 
consideration the large size of the macromolecule and thus is dependent upon 
various factors including internal motions, overall rotational correlation times, the 
geometrics of the nuclei itself, as well as the mechanistic pathway of the relaxation 
process [65]. Since these factors can vary considerably for individual 
macromolecules due to their size, relaxation behaviours and pathways can greatly 
differ. For instance, in larger proteins, the magnetization relaxes faster, which 
means that the detection time is less causing the resulting peaks to be broader and 
often much weaker. 
To understand the relaxation process, the components of the nuclear 
magnetization as it behaves in the magnetic field must be considered. The spin-
lattice or longitudinal relaxation, Rl, describes the mechanism by which the bulk 
nuclear spin magnetization (Mz) returns to equilibrium along the z-axis after being 
affected by a radio frequency. This mechanism is characterized by an associated 
relaxation time, T 1. For proteins T 1 is around one second and is around tens of 
seconds for small molecules. The relaxation rate can be related to the relaxation 
time by the equation Rl = 1/T 1. The gain and loss of magnetization in the z-direction 
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contributes to line broadening due to the inherent lifetime of the spin states. T 1 is 
associated with the peak width at half height by the relationship in Eq. (1) [66] 
v1;2 = l/rrT1 = Ri/rr (1) 
In the longitudinal relaxation process, energy is transferred from the excited 
state to the surrounding lattice, meaning that oscillation of the local magnetic fields 
in the lattice at the Larmor frequency allows for a feasible relaxation pathway [66]. 
Therefore, factors such as viscosity, temperature, molecular size, molecular 
structure, and internal forces such as Van der Waals attractions and hydrogen 
bonding can all affect the spin-lattice relaxation rates. Overall, T 1 is largely 
affected by the frequency of the nuclei ( w) as well as the time it takes the molecule 
to rotate by one radian, known as the global correlation time (Tm) [58]. Two nuclear 
spins close to each in space can be considered dipoles and experience relaxation by 
dipole-dipole coupling, which is highly dependent on the global correlation time and 
can therefore significantly contribute to Ti relaxation [67]. That is, the more rapidly 
a molecule tumbles, the less effective the dipole-dipole relaxation, and the longer 
the T 1. The contribution of the dipole-dipole relaxation mechanism to T 1 is related 
by Eq. (2) 
where yx and YH are gyromagnetic ratios of 1H and X nuclei respectively and rH-x is 
the internuclear distance [57, 66]. 
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T 1 can be measured by performing an inversion-recovery experiment where 
a 180° radio-frequency pulse is used to flip the magnetization into the negative z-
axis and then allowed to relax back into the positive z-axis (Figure 1.10). The time, 
T, it takes for the spin to return from n: (180°) to n:/2 (90°) is measured. The 
experiment is cycled many times and T is varied so that the resulting signal has 
different signs and intensities that can be plotted to observe the exponential growth 
of the peak intensity. The plotted peak intensities show the exponential signal 
growth from a short T (negative) to long T (positive) until the intensity becomes 
constant at long T. The time at which the intensity becomes constant is identified as 
T 1 and indicates the time it takes for the magnetization to equilibrate along the z-
axis [67]. 
180° goo 
delay T signal acquisition 
Figure 1.10: Inversion recovery experiment used to determine T 1. The spin system 
is first inverted with a 180° pulse, allowed to evolve during delay time T, then given 
a 90° pulse, and finally a signal is acquired. The time between the 180° pulse and 
the 90° pulse is the inversion time. Adapted from [67]. 
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Another type of relaxation process, known as spin-spin or transverse 
relaxation, R2, describes the dephasing or loss of coherence of magnetization in the 
xy-plane as the spins precess around Bo. This process is a function of time, T2, and 
has an associated relaxation rate of R2 = l/T2 [67]. The loss of coherence is a result 
of a spin having different Larmor frequencies than its neighbouring spins so that 
eventually the spin decreases in magnetization (Mxy) and decays to zero at a time 
constant T 2. The loss of magnetization is such that T 1 can be equal to T 2, but T 2 
cannot be greater than Ti (i.e. Ti~T2). This is possible when magnetization in the 
xy-plane decreases faster than the increase of magnetization along the z-axis so that 
there is a loss of signal before the spins equilibrate [5 7]. During transverse 
relaxation, there is no involvement of the z-component of magnetization, energy is 
not lost to the surrounding lattice and the energy of the transitions does not change. 
Instead, energy is exchanged between the high and low spins and the level of spin 
ordering decreases such that there is an increase in entropy of the spin system and 
no enthalpy change. In macromolecules, the transverse relaxation rates are subject 
to molecular motions that occur in the microsecond timescale [67], [57]. 
T2 can also be measured using Carr-Purcell-Meiboom-Gill (CPMG) 
experiments to enhance sensitivity of detection by measuring T 2 at constant time 
periods to obtain a complete dispersion profile in a short acquiring time. CPMG 
relaxation experiments use a spin-echo pulse sequence that has a 180° refocusing 
pulse to permit detection of conformational exchange times in the microsecond to 
millisecond timescales [57]. 
31 
The heteronuclear NOE (hetNOE) is used to gain information about the 
molecular motion properties of two unlike spins that are coupled together such as 
1sN-H and BC-H bond vectors. The hetNOE involves saturating the attached protons 
(1H) and observing the 1sN signal intensities of the amides on the fast timescale 
(pico-nanoseconds). HetNOE experiments compare 15N signals with and without 
proton saturation [ 68]. Protein regions that undergo fast motions in this timescale 
include flexible terminal ends and exposed surface loops that have below average 
hetNOE signals, which can be easily differentiated from rigid sections of a protein's 
structure. Negative signals are observed for unfolded regions that experience very 
fast motions [69]. 
1.9 PROTEIN DYNAMICS BY NMR 
In addition to structure elucidation, NMR spectroscopy is a very useful 
technique for studying protein dynamics to provide insight into function, local 
folding and unfolding, drug binding and interactions with other bio-molecules such 
as DNA and RNA. Furthermore, NMR can be used as a tool for gaining information 
about the location and energetics of conformational transformations associated 
with these interactions [70]. 
NMR dynamics can be divided into two categories: fast timescales and slow 
timescales. The motions of proteins affect NMR parameters in such a way that 
motions are either faster or slower than the time it takes for one molecule to rotate 
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an average of one radian, defined as the rotational correlation time. Depending on 
the dynamics timescale, various types of motions are observable by NMR (Figure 
1.11). Since NMR is sensitive to motions on a much slower timescale of 10-2 to 102 
seconds, NMR relaxation experiments measures protein dynamics on fast and slow 
timescales [71]. Fast timescales describe local flexibility in the picosecond (ps) to 
nanosecond ( ns) range. Slow timescales represent collective motions and occur in 
microsecond (µs) to millisecond timescales (ms). Most often slower timescales are 
measured more directly and faster timescales are limited by the rotational 
correlation time. Depending on the timescales observed, the NMR experiments 
applied could be tailored to acquire data in the most appropriate manner. 
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Figure 1.11: Timescales of protein motions observable by NMR spectroscopy. 
Adapted from [70]. 
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Fast timescale dynamics measures the spin-lattice relaxation rate (R1), the 
spin-spin relaxation rate (R2), and the hetNOE. As the protein moves, the relaxation 
observed is a consequence of local molecular motions and global molecular 
tumbling that causes instability of the local magnetic field. These motions result in a 
loss of coherence (T2 relaxation) and equilibrium restoration (T1 relaxation). 
Therefore, relaxation depends on the probability of field fluctuations of each 
frequency arising from the fluctuations of the molecule, specifically motions of the 
N-H bond vector. This probability is known as the spectral density function, J(w), 
Eq. (3) [72]. 
J(w) = Tm/(1 + w2 Tm2) (3) 
where Tm is the molecular global correlation time and w is the nuclear Larmor 
frequency. Relaxation of the 15N nucleus bonded to 1H nuclei is based on dipolar 
interactions and the chemical shift anisotropy of the system, resulting in Ri, Rz, and 
hetNOE relaxation rates given by Eq. (4), Eq. (5), and Eq. (6) respectively [73] 
l/T1 = Ri = d2/4 [J(wwWN) + 3 J(wN) + 6 J(wH+ WN)] + c2 J(wN) (4) 
l/T2 = Rz = d2/8 [41(0) + J(wwwN) + 3 J(wN) + 6 J(wH) + 6 J(wH+ WN)] + (c2/6) [4J(O) 
+ 3J(wN)] +Rex (5) 
hetNOE = 1 + (d2/4) (YN/YH) [6J(wH+WN) - J(wwwN)] Ti (6) 
where d = (µohYNYH/8rr2) (rNH-3), c = WN/-13 ( crl I - cr..L), h is Planck's constant, µ is 
the permeability of free space, WN and WH are the Larmor frequencies of 1sN and 1 H 
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respectively, YN and YH are the gyromagnetic ratios of 15N and 1H respectively, crl I 
and al. are the parallel and perpendicular components of the axially symmetric 1sN 
chemical shift tensor (1SN CSA value of 160 ppm), rNH is the bond length with typical 
values of 1.02 or 1.04 A, and Rex is the contribution to Rz from motions slower than 
the overall molecular motion. 
Once relaxation data is successfully acquired, methods for analyzing 
relaxation rates include spectral density mapping [7 4] and the model free approach 
[75, 76]. Spectral density mapping incorporates the direct relationship between the 
spectral density function and the Ri, Rz and hetNOE relaxation rates [74]. The 
model-free approach provides information about internal motions in proteins 
without forcing the Ri, Rz, and hetNOE relaxation data into any particular analysis 
model and the value of S that describes the freedom of rotational motion about the 
N-H bond vector is calculated without a model as well [76]. However, the model-
free approach requires assumptions about molecular motions and about the 
correlation function. These limitations are not present in spectral density mapping 
[77]. 
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1.10 MACROMOLECULAR CRYSTALLOGRAPHY 
Aside from NMR spectroscopy, the technique of X-ray crystallography is one 
of the main methods used for three-dimensional structure determination of 
macromolecules such as proteins. Although X-ray crystallography can only observe 
structure in a static crystal state, the benefit of this technique over NMR 
spectroscopy is simple. X-ray crystallography is not prohibited by size, which is 
very advantageous for studying large macromolecules that would otherwise exceed 
the size limit for NMR [78]. 
To solve a structure by X-ray crystallography, a crystal of the macromolecule 
of interest must first be produced. A crystal is composed of structural units of 
atoms, ions, or molecules that are a regular periodic arrangement. In this arrange of 
the crystal lattice, the smallest regular repeating unit is known as the unit cell. The 
unit cell is defined by its lattice dimensions (a, b, c) and lattice angles (a, ~' y) 
(Figure 1.12). Symmetry operations such as rotations, translations, and reflections, 
are performed on the crystal lattice unit cell that allow for a copy of the original unit 
cell to be moved in space. This copy is called the asymmetric unit [78, 79]. 
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Figure 1.12: The unit cell in a lattice crystal defined by dimensions a, b, c and 
angles a, ~, y. The origin is denoted by a dot at the vertex. Adapted from [79]. 
For protein crystallography, the crystal must be pure. This means that the 
purified and isolated protein must be a homogeneous sample that only contains the 
protein C?f interest. In general, standard protein purification methods such as 
column chromatography are sufficient for removing impurities and obtaining 
milligram quantities (usually 2-50 mg/mL) of pure sample. The difficulty in protein 
crystallography usually occurs at the crystallization step when a series of crystal 
screens are set up and optimal protein concentrations, salt, pH, and temperature 
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conditions must be met for ordered crystal formation and growth. Crystallization 
kits with pre-made buffer solutions are available for initial crystallization screening, 
upon which further optimization is required [79]. 
Since proteins are composed of amino and carboxylic functional groups that 
are readily protonated or deprotonated when in an acidic or basic environment 
respectively, proteins are often quite sensitive to small pH changes, causing proteins 
to crystallize over a small pH range in a select amount of buffers [80]. 
The solubility of the macromolecule is important for crystallization to occur. 
The macromolecule must be pulled out of a soluble state into a nucleation state that 
promotes nuclei formation from which a crystal will grow (Figure 1.13). In terms of 
phases, crystal nucleation and growth occur in the region of supersaturation. To 
reduce the solubility of the protein and control precipitation, a precipitant is 
included in the buffer system [80]. 
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Figure 1.13: Protein crystallization phase diagram. In the area of undersaturation 
the protein and/or precipitation concentrations do not produce crystal growth. In 
the precipitation zone, the protein comes out of solution as an aggregate and is not 
useful. In the area of nucleation, crystal nucleation occurs and initial crystal growth 
is facilitated. As the crystal grows, protein concentration is depleted and protein 
crystallization moves to the metastable (growth) zone. Adapted from [79]. 
39 
Two types of vapor diffusion methods are commonly used for achieving 
crystallization. The hanging drop technique, which is the most used method, 
involves mixing a few microlitres (usually 1-2 µL) of protein with an equal ratio of 
reservoir (buffer) solution containing the precipitant. This protein/precipitant 
mixture is placed on the surface of a cover slip that covers the reservoir. The buffer 
solution is also added to the reservoir in a larger volume. Since the 
protein/precipitant mixture in the drop is less concentrated than the reservoir 
solution, water -evaporates from the drop into the reservoir. As a result, the 
concentration of the protein and precipitant in the drop increases, allowing for 
protein crystal formation. The sitting drop method follows the same principles as 
the hanging drop method with the exception that the droplet is positioned on a 
pedestal or ledge above the reservoir (Figure 1.14). It is important to note that both 
the hanging drop and sitting drop methods require a closed system that is achieved 
by sealing the cover slip to the top of the reservoir with a high vacuum grease [79] 
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Hanging Drop Sitting Drop 
Figure 1.14: Two types of vapor diffusion methods commonly used for protein 
crystallization. Adapted from [79]. 
Once a protein crystal of suitable order and size is achieved, the crystal must 
be mounted in preparation for diffraction. To begin this process, a droplet of 
mother liquor with the protein crystal of interest is added to the surface of a plastic 
cover and placed under a microscope. A crystal mounting tool, such as a cryogenic 
loop, is used to select the protein crystal from the droplet. Once mounted, the 
crystal is immediately cryoprotected with liquid nitrogen and stored in a dewar 
until data is collected by a diffractometer or at a synchrotron [79]. 
At the synchrotron or diffractometer, an X-ray beam is projected at the 
crystal and thereby scattered to produce a diffraction pattern that provides 
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information about the lattice planes. This diffraction event is defined by Bragg's 
Law (Figure 1.15) [78]. 
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Figure 1.15: Bragg's Law scattering. Crystal scattering occurs in all directions, 
however it is only visible in a finite number of directions that obeys Bragg's Law. 
Adapted from [78]. 
Although scattering from the crystal occurs in all directions, scattering is only 
visible in a finite direction by wavelengths of plane waves that do not interfere with 
one another. Constructive interference occurs when nA. = 2dsin8. Perpendicular to 
the diffraction planes is a diffraction vector (S) with length that is the reciprocal to 
the spacing between the diffraction planes (1/d). The diffraction vector provides a 
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directional component to the reciprocal space unit cell parameters a*, b*, c* as 
described in Eq. (7) [78] 
S (hkl) = ha* + kb* + le* (7) 
where h, k, 1 are Miller indices and each index describes a plane orthogonal to a 
direction. The diffraction process can be understood in visual terms by the Ewald's 
Sphere, which incorporates the scalar (Bragg's Law) and vector (Miller indices) 
components of diffraction (Figure 1.16) [78]. 
Diffraction maximum 
Radius 1/A Direct beam Reciprocal 
Space origin 
Figure 1.16: Ewald's Sphere describes the requirements for diffraction as a 
graphical representation. For a diffraction point to adhere to the diffraction 
conditions, the diffraction po~nt must lie on the surface of Ewald's Sphere. Adapted 
from [78]. 
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In the Ewald Sphere construction, the crystal sits in the center of the sphere 
then the X-ray beam enters from the left and is scattered by the crystal. The beam 
that passes directly through the crystal to the surface of the sphere is called the 
origin of reciprocal space. The diffracted beams have an angle of 28 from the origin 
of reciprocal space. In order for a diffracted beam to appear in the crystal's 
diffraction pattern, the diffraction point must lie on the surface of the Ewald's 
Sphere, thus satisfying the diffraction condition. By using this diagram, it is possible 
to determine which points satisfy to the diffraction condition, making data collection 
easier to interpret [78]. 
1.11 SMALL ANGLE X-RAY SCATTERING (SAXS) 
A wealth of information about a protein's three-dimensional structure can be 
gained from the high-resolution techniques of NMR spectroscopy and 
crystallography. In addition to both these methods, small angle X-ray scattering 
(SAXS) is an established low-resolution technique that is commonly used as a 
fundamental structural analysis tool for the study of biomolecules to obtain 
structural information about the shape and size of a protein [81-83]. Unlike 
crystallography, a crystalline sample is not needed for SAXS experiments and the 
sample is not destroyed in the process. Although this is an advantageous quality for 
protein samples that are difficult to crystallize, the loss of information due to the 
random orientation of dissolved or partially ordered molecules, compared to 
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crystallography, is a disadvantage [81]. Another benefit of SA.XS is that unlike NMR 
methods, SA.XS experiments are not limited by biomolecular size. Most often SA.XS is 
employed to compliment NMR and crystallography methods and by doing so, useful 
structural information can be obtained [81, 84]. 
In a standard SA.XS experiment, a monochromatic and collimated X-ray beam 
illuminates macromolecules to produce a scattering pattern that is recorded by an 
X-ray detector. Intensity (/) of the scattering is isotropic and is dependent on the 
scattering angle 20 [81]. Measurements of the buffer serve as a blank and the 
scattering intensities of the buffer are subtracted from the scattering intensities of 
the sample. The result is a scattering profile that is expressed as a function of the 
momentum transfers s = 4n:sin0/A., where A. is the wavelength. The value of "s" is 
proportional to the solute concentration and to the scattering from a single particle 
when all orientations are averaged. The scattering profile provides information 
about the main geometrical parameters of the particle, such as molecular mass 
(MM), hydrated particle volume (V), specific surface area (S), the maximum distance 
within the particle (Dmax), and the folding state of the particle. Most significantly, the 
one-dimensional scattering profile provides useful information about the three-
dimensional macromolecular structure. The low-resolution (1.5-2nm) capability of 
SA.XS allows for ab initio particle shape predictions to be produced from the 
scattering pattern intensity [81]. It must be noted that multiple shapes may be 
compatible with the same scattering profile; however, this can be limited by 
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including restrictions to the parameters used when composing the macromolecule 
model. 
The SAXS method is often used to identify biologically active conformations 
and oligmeric compositions, to determine flexible systems quantitatively, and to 
corroborate the structural similarity between crystal and solution states by quickly 
computing ab initio biomolecular shapes and sizes [81-83, 85]. Because of such 
applications, SAXS remains to be a useful technique for studying biomolecules that 
are well behaved in solution. 
1.12 ISOTHERMAL TITRATION CALORIMETRY {ITC) 
In addition to NMR spectroscopy, biomolecular interactions can be further 
characterized from an energetic perspective using the th.ermodynamic technique of 
isothermal titration calorimetry (ITC). ITC directly measures the heat released and 
absorbed during a biomolecular binding interaction to generate accurate 
thermodynamic parameters, making it possible to determine the binding constant 
(Ka), reaction stoichiometry (n), entropy (~S) and enthalpy (~H) values. The result 
is a complete thermodynamic profile of a biomolecular interaction [86]. 
The versatility of ITC allows common interactions to be studied easily and 
quickly, including protein-protein, protein-nucleic acid, protein-small molecule, and 
antibody-antigen interactions. In addition, a range of applications can be studied 
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including binding characterizations, enzyme kinetics, biological activity assessment, 
and studies of the effects of structural changes on binding mechanisms [87]. 
A major advantage of using this analytical technique is that Kd binding 
affinity values can be accurately measured in the millimolar to nanomolar range in a 
single experiment. Binding constants as large as 108-109 M-1 can be measured and 
heat changes as small as 0.4 µJ (0.1 µcal) can be detected with considerable 
accuracy. Furthermore, single and multiple binding sites can also be detected [88]. 
The ITC apparatus manufactured by Microcal (USA) is designed to titrate a 
solution of biomolecule (A) from a syringe into a cell containing a solution of the 
associated binding ligand (B) (Figure 1.17) [89]. Most often the small molecule is 
titrated into the macromolecule, but this is not a rule. 
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Figure 1.17: Isothermal titration calorimetry (ITC) apparatus. Adapted from [89]. 
The heat released or absorbed from the binding interaction upon titration is 
then monitored over a period of time with the raw data represented as peaks on a 
chromatogram (Figure 1.18, top panel). The largest ITC signal is generated when A 
is added to B because all of B is available for binding and a significant amount of A is 
bound. As less B becomes available, the ITC signal diminishes. The amount of heat 
absorbed or released during the titration is directly proportional to the amount of 
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binding such that when B is fully in complex to A, there is no B available for binding 
and no heats of reaction are observed. Instead, heats of dilutions can be subtracted 
from the data if needed. Integration of the heats produced from each titration 
generates a binding isotherm curve (Figure 1.18, bottom panel) that is plotted 
against the heats from each injection and the molar ratio of the binding partners. 
The curve is fit to either a one-site or multiple-site binding model. 
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Figure 1.18: Output given by the ITC apparatus. The top panel is a graph of the 
power supplied per unit time recorded in real time. Integrating the data in the top 
panel provides the heat per mole per injection with respect to the molar ration, as 
shown by the bottom panel. Adapted from [89]. 
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The binding model selected is representative of the binding process used to 
calculate Ka, ~H, and n. From these thermodynamic parameters, the change in free 
energy (~G) can be calculated using Eq. (8) 
~G = -RT lnKa (8) 
where R is the gas constant and T is the temperature of the system in Kelvin. From 
this, the change in entropy can be determined from Eq. (9) 
~G = ~H-T~S (9) 
Spontaneous ligand-macromolecule interactions are when ~G is negative, which can 
occur during exothermic reactions when ~H is negative and ~Sis positive. 
Information about the binding affinity, Kd, can be determined using Eq. (10) 
Kd = 1/Ka (10) 
Determination of binding affinity is an important quantitative aspect when 
considering molecular interactions [89]. 
1.13 GEL AFFINITY ELECTROPHORESIS 
Macromolecules are commonly separated and analyzed using 
electrophoresis. This technique separates molecules based on electric charge and 
so 

electrophoresis analysis has been shown to generate precise quantitative data. 
Investigating the interaction between protein drugs and their molecular targets is 
particularly useful when developing stable protein pharmaceuticals [93]. For 
example, binding constants have been estimated for the interaction between the 
immunosupressive drug cyclosporine A (CsA) to the enzyme cyclophilin (Cyp) [94]. 
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CHAPTER2 
A STRUCTURAL STUDY OF C. ELEGANS RDE-4, A DUAL DOUBLE STRANDED 
RNA-BINDING PROTEIN INVOLVED IN RNA INTERFERENCE 
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2.0 RDE-4: THE DUAL DOUBLE STRANDED RNA-BINDING PROTEIN 
The usage of short RNA molecules as gene regulators has gained significant 
interest since the discovery of siRNA [29]. Small interfering RNAs (siRNAs) are a 
class of double stranded RNA that is cleaved into short sequences of approximately 
22 nucleotides in length, and have an integral role in RNA interference (RNAi). The 
process of RNAi uses siRNA to bind to a complimentary target mRNA, thus tagging 
the mRNA for degradation and ultimately controlling gene expression [29]. For this 
reason, RNAi is critical for our understanding of cell development, cell growth, and 
consequently for our understanding of the molecular basis of cancers. 
Double stranded RNA binding proteins ( dsRBPs) in the RNAi pathway act in 
concert with the endonuclease, Dicer-1 (DCR-1 ), to cleave exogenous or endogenous 
double stranded RNA into short interfering RNA (siRNA) [95]. The antisense strand 
of the siRNA is bound to the RNA induced silencing complex (RISC) and 
subsequently base paired to a strand of mRNA, causing strand degradation. In C. 
elegans, the dsRBP component in the DCR-1 complex is RDE-4, which contains two 
dsRNA binding domains ( dsRBDs) that are each composed of a conserved af3f3f3a 
fold. RDE-4 is necessary to process the trigger RNA into siRNA, most likely through 
binding the dsRNA and recruiting it to the DCR-1 complex (Figure 2.1) [96]. 
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Figure 2.1: The early events of RNA interference. 1) The dual dsRNA binding 
protein RDE-4 (green) forms a complex with the Dicer endonuclease (grey) to bind 
the target dsRNA. 2) The Dicer complex cleaves the target dsRNA into siRNA 
molecules. 3) The siRNA molecules are available for incorporation into the RNA 
induced silencing complex (RISC) where it can perform gene regulation tasks. 
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RDE-4 contains a dual double-stranded RNA binding domain (dsRBD), each 
predicted to be composed of a a~~~a motif (Figure 2.2). The full protein sequence 
of RDE-4 is 385 amino acids (aa) long. The first dsRBD is located from 43-105aa and 
the second dsRBD is located from 169-236aa. A linker region of approximately 63aa 
separates the two dsRBDs. In addition, the C-terminal (254aa-385aa) is necessary 
for the dimerization of the protein, resulting in the formation of a stable homodimer. 
Although the C-terminal is not required for dsRNA binding or binding with 
increased affinity, it is believed to facilitate the formation of an active Dicer complex 
[96]. In the case of Rntlp, a dsRBD containing protein in the RNase III family, the 
helical region that flanks the main dsRBD has been found to control the binding 
specificity of the protein [97, 98]. 
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Figure 2.2: The a~~~a motif present in RDE-4. The cylinders outlined in red 
represent a-helices, the arrows outlined in blue represent the B-strands, the boxed 
regions indicates the two dsRBDs (based on PSIPRED protein structure prediction 
program). 
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The characterized function of the a~~~a motif in RDE-4 is to bind structured 
RNA strands, more specifically dsRNA molecules. Although RDE-4 can bind short 
dsRNA, the affinity for long dsRNA is much higher. For example, RDE-4 can bind a 
650 base-pair (bp) dsRNA with a Kd of-23 nM compared to a 20 bp dsRNA with a Kd 
of-1.5 µM [96]. 
Structural studies performed by Chang et al. [99], reveal that the dsRBD of 
RNA binding proteins can bind across approximately 15-16 RNA base pairs by 
interacting with the 2'0H groups and phosphates groups of the successive minor, 
major, and minor grooves in an RNA duplex (Figure 2.3). This binding interaction is 
believed to apply to the dual dsRBD of RDE-4 [99]. Both dsRBDs of RDE-4 are 
required for RNA binding and RDE-4 can bind dsRNA independently of DCR-1 with 
high affinity for long dsRNA (;:::40 base pair), but not short dsRNA molecules. This 
binding specificity is consistent with the function of the DCR-1 complex to bind the 
trigger dsRNA, but not the product siRNA molecules [96]. 
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Figure 2.3: The binding interaction of dsRBD and dsRNA in Xenopus /aevis RNA 
binding protein A The first a-helix in the dsRBD, loop4, and loop2 are able to 
interact with the minor, major, minor grooves of the dsRNA [99]. 
It must be noted that many different dsRNA-binding proteins in different 
RNAi pathways in various organisms have been discovered, with most of these 
proteins identified to contain a dsRBD. In most cases, only a single copy of the 
dsRBD is present. However, proteins that have two dsRBD regions have been 
reported, including adenosine deaminase (ADAR) [100] and protein kinase (PKR) 
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[101]. The two dsRBD structures in both these proteins do not interact with each 
other, thereby operating as independent structured units. When the structure of the 
protein involved in human RNAi, DGCR8, was reported in 2007, DGCR8 became the 
first dual dsRBD protein in RNAi to have its structure determined as well as the first 
example of a dual dsRBD protein with two dsRBD regions that interacted with each 
other to create a single ordered structure [102]. The structure of DGCR8 that was 
reported identified the conserved a~~~a motif in both dsRBD regions. In addition, a 
helix in the region between the two dsRBD structures and another helix at the C-
terminus was found to interact with the second helix in the first dsRBD to create a 
structured single unit of the tandem dsRBDs (Figure 2.4). 
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Figure 2.4: Domain structures and sequence alignments of dual dsRBD family of 
proteins, Drosophila R2D2, C. elegans RDE-4, and Human DGCR8. In panel A, the 
domain locc;ition of the dsRBDs and C-terminal domain (CTD) within the protein 
family is shown. In panel 8, the sequence alignment of the proteins is shown where 
"H'' and "E" indicate a-helix and ~-strand secondary structures contained in the 
dsRBD regions of DGCR8 respectively, and "h" and "e" indicate the a-helix and ~-
strand secondary structures outside of the dsRBD regions of DGCR8. Residues 
conserved in all three family members are indicated by "*", residues conserved in 
two of the three family members are indicated by ":", and residues with similar 
function are indicated by".". 
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2.1 RESEARCH GOALS 
The purpose of this project was to understand how the Dicer complex 
recognizes the trigger RNA by determining the structures of the dual dsRBD-
containing protein and studying how they interact with RNA More specifically, this 
project aims to understand how the structure of the dual. dsRBD interacts with 
dsRNA by identify if the dual dsRBD of the C. elegans RDE-4 protein forms a single 
structured unit to allow for binding to long target dsRNA and not to short product 
dsRNA molecules. Answering this question will provide a structural explanation for 
how this binding specificity is achieved in the RNAi pathway. Proteins that contain 
dsRNA-binding domains are necessary during the initial steps of RNAi to process the 
trigger dsRNA into siRNA products [95]. However, the mechanism by which the 
dsRNA binding protein is capable of binding the dsRNA is not well understood. 
Furthermore, this research aimed to investigate which residues in the protein 
sequence interact with RNA and are important for RNA binding to occur, and to 
provide insight into the tertiary structure of these dsRBDs. To achieve these goals, 
the function and structure of the dual dsRBDs of RDE-4 was investigated through 
the techniques of NMR spectroscopy, small angle X-ray scattering (SAXS) data, 
isothermal titration calorimetry (ITC), and gel shift assay. 
The ability of RNAi to silence the activity of specific genes has directed the 
use of RNAi to being a therapeutic modality [103]. Understanding the RNAi 
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mechanism will certainly prove advantageous towards the progression of RNAi-
based therapies. 
2.2 MATERIALS AND METHODS 
2.2.1 Assembly ofRDE-4 dual dsRBD Protein Truncations 
(i) Truncations Made Via Assembly PCR (RDE-4-38-268) 
Oligomers of two selected regions (22aa-268aa and 38aa-268aa) of the RDE-
4 DNA sequence were determined using Assembly PCR Oligo Maker [104] and were 
provided by Sigma-Aldrich. The oligomers were subjected to assembly polymerase 
chain reaction (PCR) in order to obtain the two template DNA regions of interest. 
The assembly PCR products were analyzed on a 1.5% agarose gel for confirmation 
of size. The assembly PCR product corresponding to the template DNA encoding for 
RDE-422-268 was amplified by PCR using Vent Polymerase and the forward primer 5' -
CCGGGAATTCTCCCGTTC-3' (Sigma-Aldrich) and the reverse primer 5'-
CGGCCAAGCTTTTTAATCTTGG-3' (Sigma-Aldrich). Similarly, the template DNA 
encoding for RDE-438-268 was amplified by PCR using the forward primer 5' -
CCGGGAATTCATGTTTCTGAAGA-3' (Sigma-Aldrich) and the reverse primer 5'-
CGGCCAAGCTTTTTAATCTTGG-3' (Sigma-Aldrich). All forward and reverse primers 
included 3' EcoRI and 5' HindIII restrictions sites, respectively. The PCR products 
were analyzed on a 1.9% low melt agarose gel. The DNA bands of interest were 
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excised from the gel and the DNA extracted using the Qiagen Qlquick DNA Gel 
Extraction Kit. Double digestion reactions using EcoRI and HindIII restriction 
enzymes were performed on the inserts and on a pET23a vector. This involved a 3-
hour incubation time followed by heat inactivation of the restriction enzymes at 
65°C for 20 minutes. To prevent the digested vector from self-ligating, the 5' 
hydroxyl group of the DNA was removed by incubating with Antarctic Phosphatase 
for 1 hour at 37°C, then heat inactivating the enzyme at 65°C for 15 minutes. Each 
insert was ligated to pET23a vectors by incubating the reaction with T4 DNA Ligase. 
The ligated plasmids were transformed to DH5aF' E. coli competent cells by heat 
shocking and incubated overnight at 3 7°C on kanamycin agar plates. Colony PCR 
was used to determine if the cells contained the inserts of interest. The colony PCR 
reactions were analyzed by 1. 9% agarose gel, which determined that only the insert 
of RDE-438-268 was successfully ligated to the vector. The Sequencing Lab in the Core 
Facility at York University sequenced the DNA of this colony. After receiving 
positive sequencing results, the plasmid was transformed via heat shocking to BL21 
(DE3) E. coli expression cells. 
(ii) Truncations Made Via GenScript (RDE-428-253, RDE-428-137+165-253, RDE-4253-385) 
The following three regions of the full RDE-4 DNA sequence were obtained as 
plasmids (in pET15b vectors) and as ToplO stab cultures by GenScript: RDE-428-253, 
RDE-428-137+165-253, and RDE-4253-385. These truncations contained the dual dsRBDs, 
the dual dsRBDs without the region of residues that links the two dsRBDs together, 
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and the C-terminus respectively. The plasmids were transformed to BL21 (DE3), 
and BL21 (pLysS) E.coli competent expression cells by heat shocking and incubated 
overnight at 37°C on ampicillin LB agar plates. 
2.2.2 Protein Expression ofRDE-4 Protein Truncations 
Expression tests were performed on all truncations mentioned in section 
2.2.1 (i) and {ii) that were transformed to BL21 (DE3) expression cells. To 
determine expression, the cells were grown in small-scale culture growths of 5 mL 
TYP growth media with 5 µL of the appropriate antibiotic in the shaker at 3 7°C, and 
then induced with 1.0 mM Isopropyl-(3-D-thiogalactopyranoside (IPTG) when the 
O.D6oo reached 0.8. The uninduced and induced samples were analyzed on 15% 
SDS-PAGE gels. Once successfully expression was confirmed, large-scale growths of 
the each domain were made in two 1 L flasks of TYP media containing 1 mL per flask 
of the appropriate antibiotic. The cells were induced with 1.0 mM IPTG when O.D6oo 
reached 0.8, then incubated for 4 hours at 37°C in the shaker. After the incubation 
period, the media was centrifuged for 20 minutes at 5,000 rpm. The supernatant 
was discarded and the pellet resuspended in wash buffer (30 mM Tris pH 8, 250 mM 
NaCl, 5 mM BME, 5% Glycerol, 0.02% NaN3). 
2.2.3 Protein Purification ofRDE-4 Protein Truncations 
The cells were sonicated using a Fisher Scientific Model 500 Sonic 
Dismembrator (6 cycles: 30 seconds pulse on, 30 seconds pulse off) and centrifuged 
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at 15,000 rpm for 20 minutes. Both the supernatant and pellet were separated and 
retained. The pellet was resuspended in 15 mL of 6 M guanidine hydrochloride 
(GdnHCl) and allowed to gently shake overnight at 4°C. Following centrifugation at 
15,000 rpm for 30 minutes, the supernatant was passed through a 5.00 µm filter 
then a 0.45 µm filter. The supernatant was purified using a nickel affinity column 
under denaturing conditions (denaturing buffer: 6 M GdnHCl, 30 mM Tris pH 8, 250 
mM NaCl, 5 mM BME, 5% (v /v) Glycerol, 0.02% (w /v) NaN3; wash buffer: 30 mM 
Tris pH 8, 250 mM NaCl, 5 mM BME, 5% (v /v) Glycerol, 0.02% (w /v) NaN3; elution 
buffer: 400 mM imidazole, 30 mM TrisHCl pH 8, 250 mM NaCl, 5 mM BME, 5% (v /v) 
Glycerol, 0.02% (w/v) NaN3). Fractions containing the protein of interest were 
collected and analyzed by 15% SDS-PAGE gel. The fractions containing the purified 
protein of interest were concentrated using a 10,000 molecular weight cut-off 
(MWCO) Amicon concentrator and the buffer exchanged to a Q anion exchange 
column wash buffer (20 mM Tris pH 7, 0.5 mM EDTA, 0.5 mM DTT, 0.02% (w/v) 
NaN3) for further purification. The resulting sample (-1.5-2.0 mL) was loaded and 
purified on a Q anion exchange column using the same wash buffer as in the sample 
and an elution buffer containing 1 M NaCl, 20 mM Tris pH 7, 0.5 mM EDTA, 0.5 mM 
DTT, and 0.02% (w /v) NaN3. The fractions containing the protein of interest were 
collected and analyzed on a 15% SDS-PAGE gel and concentrated to 500 µL using a 
10,000 MWCO Amicon concentrator. 
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2.2.4 RDE-4 dsRBDs NMR Sample Preparation 
The pET15b plasmid containing the RDE-4 DNA sequence encoding from 
amino acids 28-253 was obtained from GenScript (2.2.1 (ii)). The plasmid was 
transformed into E. coli BL21 (DE3) competent expression cells by heat shocking 
and incubated overnight at 37°C on ampicillin LB agar plates. Cells were isotopically 
labeled with tsN, 15N13C, or 2H15N13C by growing 1L cultures of cells in minimal 
media containing the isotope or isotopes of choice along with 1 mL of ampicillin 
antibiotic (100mg/mL). Note that protein expression was enhanced by adding 10% 
of the total media volume of the appropriate isotopically labeled Spectra 9 growth 
media to the prepared minimal media. Protein expression was induced with 1.0 mM 
IPTG at O.D6oo=0.6-0.8 followed by a 4 hour growth period. The cells were sonicated 
using a Fisher Scientific Model 500 Sonic Dismembrator (6 cycles: 30 seconds pulse 
on, 30 seconds pulse off) and centrifuged at 15,000 rpm for 20 minutes. Both the 
supernatant and pellet were separated and retained. The pellet was resuspended in 
15 mL of 6 M guanidine hydrochloride (GdnHCl) and allowed to gently shake 
overnight at 4°C. Following centrifugation at 15,000 rpm for 30 minutes, the 
supernatant was passed through a 5.00 µm filter, a 0.45 µm filter, and finally a 0.22 
µm filter. The supernatant was refolded and purified using a nickel affinity column 
(denaturing buffer: 6 M GdnHCl, 30 mM Tris pH 8, 250 mM NaCl, 5 mM BME, 5% 
(v /v) Glycerol, 0.02% (w /v) NaN3; wash buffer: 30 mM Tris pH 8, 250 mM NaCl, 5 
mM BME, 5% (v /v) Glycerol, 0.02% (w /v) NaN3; elution buffer: 400 mM imidazole, 
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30 mM TrisHCl pH 8, 250 mM NaCl, 5 mM BME, 5% (v /v) Glycerol, 0.02% (w /v) 
NaN3). Column fractions were collected and analyzed by 15% SDS-PAGE gel. The 
fractions containing the purified protein of interest were concentrated down to a 
volume of 500 µL using a 10,000 molecular weight cut-off (MWCO) Amicon 
concentrator. All NMR samples were prepared by exchanging the sample buffer 
(using a 10,000 Amicon concentrator) with a buffer that contained 50 mM KH2P04, 
SO mM KzHP04, 250 mM NaCl, 0.5 mM DTT, 0.02% (w /v) pH 7.0. In addition, 10% 
(v /v) DzO was added to all NMR samples. The final sample volumes for all NMR 
samples were no less than SOOµL at concentrations of approximately 1 mM. 
Binding studies (1:1 complex) of the RDE-4 dual dsRBD and 83mer RNA by 
NMR spectroscopy were completed at concentrations of 0.15 mM in a shegimi NMR 
tube. Buffer used for the complex was identical as used for all NMR experiments. 
2.2.5 RDE-4 dsRBDs NMR Processing and Analysis 
All NMR spectra were acquired on a Bruker Avance 600 MHz and Bruker 800 
MHz NMR spectrometers. All NMR spectra were processed for NMRView software 
[105]. Analysis of the acquired 2D and 3D NMR data were performed using CcpNMR 
Analysis 2.0.6 and NMRViewJ 8.1 NMR spectra software. 
2.2.6 RNA Synthesis of 83mer Oligo for RDE-4 dsRBD Binding Studies 
RNA for binding studies were transcribed from either a 100mer DNA strand 
annealed to a Topl 7 promoter sequence or from two 100mer DNA complimentary 
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strands annealed together to make a double stranded template for RNA synthesis. 
All RNA 40 mL large-scale reactions were ethanol precipitated and purified on a 
20% large scale (19:1, acrylamide:bisacrylamide) polyacrylamide 6 M urea gel that 
ran at 25 W for 24 hours. The band containing the RNA was excised and 
electroeluted using an Elutrap at 100 V overnight. Samples were collected and 
concentrated using a 3,000 MWCO Amicon concentrator. The samples were 
exchanged 4 times with 2 mL of 1 M NaCl and then washed 4 times with 2 mL of 
distilled water to a final volume of-500 µL. 
2.2.7 Gel Shift Binding Studies of the Dual dsRBD Region ofRDE-4 to a Long 
dsRNA 
Samples of the complex were prepared of RDE-428-253 (1.2 µM) and an 83mer 
RNA oligo (1.4 µM) at a molar ratio of approximately 1:1 of protein to RNA, followed 
by increasing protein concentrations of lOX, lOOX, and lOOOX. Subsequently, the 
reaction mixtures were run on 8% native (19:1, acrylamide:bisacrylamide) at 300 V 
for 35 minutes polyacrylamide gels, allowing for visualization of the protein-ma 
complexes. 
2.2.8 ITC Study of RDE-4 Dual dsRBD:83mer RNA Complex 
Isothermal titration calorimetry (ITC) was performed using a MicroCal VP-
ITC instrument. All samples were in the identical buffer as used for the NMR 
experiments. The sample buffers were degassed using the MicroCal Thermovac. 
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Based on the gel shift assays, it was decided that titrating 2.5x molar ratio of protein 
into the RNA would be sufficient for binding to occur. Titrations were performed by 
injecting 2 µL of protein (0.263 mM) followed by 34 consecutive injections of 8 µL 
aliquots of protein (0.263 mM) into the ITC cell containing 83mer RNA (20 µM). All 
titrations were performed at 25°C. Enthalpy, equilibrium association constant and 
binding stoichiometry was determined by fitting the data to one-site and two-site 
binding models using Origin 5.0 (MicroCal Software Inc). 
2.2.9 Crystal Screen Trials 
Unlabeled protein samples of the RDE-4 dsRBDs were grown and purified as 
mentioned above with the exception of TYP media being used instead of minimal 
media containing isotopes. The final protein concentration of the RDE-4 dsRBDs for 
all screens was 0.5 mM (12.8 mg/mL) when in a buffer of 20 mM Tris HCl (pH 7.0), 
400 mM NaCl, 0.5 mM EDTA, 0.02% (w/v) NaN3. Crystallization screens of the RDE-
4 dsRBDs protein were set up using the Qiagen N eXtal Classics Crystallization Kit via 
hang drop method. Optimized crystal screens were prepared under buffer 
conditions of 0.2 M sodium Citrate, 0.1 M Tris HCl (6.0, 7.0, 8.0, and 9.0), and PEG 
(20%, 25%, 35%, and 40% (v /v)). Crystallization screens of the RDE-4 dsRBDs were 
also prepared using the Qiagen NeXtal PEGs I Suite, Qiagen NeXtal PEGs II Suite, 
Qiagen NeXtal JCSG+ Suite, and Qiagen NeXtal MPDs Suite. 
Samples (15N labeled) of the RDE-4 dsRBDs protein and the 83mer RNA were 
also prepared (see sections 2.1.2, 2.1.4, 2.1.6) for crystal screening at Dr. Matthew 
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Wilce's laboratory at the University of Melbourne in Austalia. The samples prepared 
were as follows: 1) free RDE-4 dsRBDs protein (34 mg/mL), 2) 83mer RNA (34.4 
mg/mL). Crystal screens of these samples were performed by Simone Beckham in 
Dr. Matthew Wilce's laboratory. 
2.2.10 SAXS Sample Preparation 
lsotopically labeled samples are not required when performing SAXS, 
however the samples of RDE-4 were 15N labeled. The protein expression and 
purification of the RDE-4 was performed as described in sections 2.1.2 and 2.1.4. 
The 83mer RNA was prepared as described in section 2.1.6. The samples prepared 
for SAXS experiments were as follows: 1) free RDE-4 protein, 26 KDa (20 mg/mL), 
2) 83mer RNA, 27 KDa (20 mg/mL) and 3) RDE-4 protein:83 mer RNA complex, 53 
KDa (20 mg/mL). All SAXS experiments were performed and analyzed by Simone 
Beckham in Dr. Matthew Wilce's laboratory at the University of Melbourne in 
Australia. The ab initio derived structural envelope for RDE-4 was calculated using 
GASBOR [106]. 
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2.3 RESULTS AND DISCUSSION 
2.3.1 Protein Expression, Purification, and NMR Analysis 
At the start of this project, a truncation of the dual dsRBD from amino acids 
38-268 (RDE-438-268) was desired for cloning and expression. After many attempts, 
the RDE-438-268 truncation was successfully cloned into pET23a plasmids, 
transformed to DHSaF' E. coli cells and expressed in BL21 (DE3) E. coli competent 
cells (2.2.1 (i)). Purification of RDE-438-268 by nickel affinity column yielded a 
sample that was pure enough for NMR analysis by 15N HSQC. However, the HSQC of 
the 15N RDE-438-268 NMR sample showed fewer than the expected number of peaks 
that was characteristic of an unfolded protein. It was suspected that the a-helix 
secondary structure preceding the RDE-438-268 truncation was necessary for proper 
protein folding. 
To investigate the necessity of particular regions of the protein for dsRNA 
binding and to obtain a workable protein for further studies, the viability of three 
new truncations were explored. RDE-428-253 was a truncation of RDE-4 from amino 
acids 28-253. RDE-428-137+165-253 was a truncation of the dual dsRBD without the 
linker region that exists between the two domains (2.2.1 (ii)). RDE-4253-385 was a 
truncation of the C-terminus region. Unlike the previous truncation, RDE-438-268, 
these three truncations were designed to include an additional a-helix predicted at 
the N-terminus of the first dsRBD to encourage proper refolding of the protein. 
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All three truncations were expressed in BL21 (DE3) and BL21 (pLysS) E.coli 
competent expression cells to determine which construct expressed the most 
amount of protein. Analysis of all protein expression on a 15% SDS-PAGE gel 
showed expression of RDE-428-253 (dual dsRBD) (Figure 2.5, 1A-1B) and RDE-4253-385 
CC-terminal, 23 KDa) (Figure 2.5, 3A-3B) in both expression cells. However, 
expression in BL21 (DE3) cells proved to produce the most amount of protein of 
both truncations compared to BL21 (pLysS) cells. As a result, BL21 (DE3) 
transformants were used for all subsequent culture growths. The molecular weights 
of RDE-428-253 and RDE-4253-385 were 28 KDa and 16 KDa respectively. There was no 
expression of RDE-428-137+165-253 (dual dsRBD without the linker region) (Figure 2.5, 
2A-2B) in either of the expression cells, indicating that the two dsRBDs of RDE-4 in 
C. elegans cannot be expressed without the linker. The molecular weight of RDE-428-
137+165-253 was 23 KDa. 
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Figure 2.5: Protein expression of RDE-4 protein truncations on a 15% SDS-PAGE 
gel from 0-3 h. lA is RDE-428-253 in BL21 (DE3) cells and 18 is RDE-420-253 in 8L21 
(pLysS) cells. 2A is RDE-428-137+165-253 in 8L21 (DE3) cells and 28 is RDE-428-137+165-
253 in 8L21 (pLysS) cells. 3A is RDE-4253-385 in 8L21 (DE3) cells and 38 is RDE-4253-
·395 in 8L21 (pLysS) cells. Expression was seen only for RDE-428-253 and RDE-4253-385, 
with optimal expression occurring in 8L21 (DE3) cells. "M" is the protein marker, 1 
and 2 are uninduced and induced (1 mM IPTG) samples respectively, and "*" 
indicates expression of the protein of interest. 
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Truncation RDE-428-253 containing the dual dsRBD was selected for further 
studies. Note that from this point forward, the RDE-428-253 construct is referred 
interchangeably with RDE-4 or RDE-4 dsRBDs. Since protein expression was 
observed in unlabelled growth media, a large scale culture growth of 15N minimal 
media was prepared in order to later observe the isotopically labeled protein using 
NMR spectroscopy. Analysis by a 15% SDS-PAGE gel confirmed protein expression 
in minimal media (Figure 2.6). 
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Figure 2.6: Protein expression of 15N-labelled dual dsRBD of RDE-4 on a 15% SDS-
PAGE gel after 0 h, 1.5 h, and 3 h. "M" is the protein marker, 1 and 2 are uninduced 
and induced (1 mM IPTG) samples respectively, and "*" indicates expression of the 
protein of interest, RDE-4. 
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After sonication of the cells, analysis of the lysate and pellet revealed that the 
protein was insoluble. In order to solubilize the protein, the pellet was resuspended 
with 6M guanidine hydrochloride (GdnHCl) and allowed to gently shake at 4 °C 
overnight. GdnHCl was used because of its ability to denature proteins by disrupting 
non-covalent bonds, hence making the protein soluble. After centrifuging the 
mixture the following day, the protein was found to be in the supernatant. 
A nickel column was used as a means to refold the denatured protein, purify, 
and then elute it. This process of on-column refolding [107] allowed the denatured 
protein to gradually refold over a linear GdnHCl gradient from 6M to OM. As a 
result, the occurrence of the protein precipitating out of solution due to a sudden 
denaturant concentration change was avoided. Throughout the course of this 
project, the on-column refolding method had repeatedly proved to be an efficient 
way of refolding proteins compared to conventional dialysis methods. A nickel 
affinity column was used to refold RDE-4 because the protein was tagged with a 
hexahistidine tag, which allowed the protein to bind to the column for the refolding 
process, then elute during the purification step once it was refolded. This type of 
column has Ni2+ beads stationed inside it that would bind to the electron-rich tag of 
the protein. The protein of interest would then be eluted off the column by adding 
increasing amounts of imidazole, which would compete for the Ni2+ beads. 
RDE-4 was found to elute at -40% imidazole concentration (Figure 2.7). The 
resulting nickel affinity fractions were analyzed by 15% SDS-PAGE (Figure 2.8). 
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Figure 2.7: Chromatogram of 15N RDE-4 dsRBDs nickel affinity column purification. 
The protein refolding step is shown by the first gradient in green. The elution step 
is shown by the second gradient in green. Absorbances (UV280nm) are in blue. 
Fractions are indicated in red. "*" indicates the protein of interest. 
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Figure 2.8: 15% SDS PAGE gel analysis of chromatogram peak fractions (F24-F31). 
15N Rde-4 dsRBDs were eluted in fractions F24-F30. "M" is the protein marker. 
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Concentration of fractions containing RDE-4 followed by buffer exchange to 
the NMR buffer consistently resulted in samples with a protein concentration of -4 
mM at 1 mL. Although the NMR sample was not completely pure, RDE-4 was in 
much higher concentration compared to all other proteins, which was sufficient for 
NMR studies (Figure 2.9). 
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Figure 2.9: Purified lSN RDE-4 dsRBDs on a 15% SDS PAGE gel. 
2.3.2 NMR Analysis of RDE-4 dsRBDs 
Many previous preliminary experiments conducted have determined that the 
28 KDa RDE-4 dsRBDs protein expresses well and can be purified clean enough for 
NMR purposes with final protein sample concentrations in the range of 4 mM. 
However, to obtain better resolved NMR data, all NMR samples were diluted to 
approximately lmM. 
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Excellent 2D and 3D data were acquired from the experiments performed on 
the Bruker 800MHz. The raw data for the 1sN-HSQC (Figure 2.10), HNCO, HNCA, 
HNCOCA, HNCACB, HCCH-TOCSY, HCCH-COSY, 1sN-NOESY HSQC, and 13C-NOESY 
HSQC (aliphatic optimized and aromatic optimized) experiments were processed to 
obtain the corresponding spectra. 
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Figure 2.10: 15N HSQC of a 1 mM sample of RDE-4 dsRBDs. The expansion of the 
boxed region shows well-dispersed peaks. 
CcpNmr Analysis 2.0.6 software was used to peak pick all of the acquired 2D 
and 3D spectra in order to generate residue assignments. Submission of the peak 
lists to the PINE Server v.1.0 produced inconclusive and misleading residue 
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assignment output data. As a result, it was determined that in order to achieve any 
useful PINE Server v.1.0 assignment probabilities, additional 30 NMR experiments 
must be conducted to obtain a more complete set of spectral data for analysis. This 
was not surprising since the RDE-4 dsRBDs protein being studied was very large 
(226 amino acids). 
2.3.3 Chemical Shift Assignments of the Dual dsRBD Region ofRDE-4 
Assignment of the backbone HN, N, Ca and C~ chemical shifts of the RDE-4 
dsRBDs were completed by acquiring and analyzing data from CBCACONH, HNCACB, 
HNCA, HNCACO, and HNCO experiments. The peaks in the lH_lSN HSQC that were 
most intense with the least amount of peak overlap upon increasing the contour 
levels were assigned first using the HNCACB and CBCACONH as a guide (Figure 
2.11). 
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Figure 2.11: HNCACB and CBCACONH strips of RDE-42s-2s3 used for assigning the 
backbone amides. Red peaks in the HNCACB strips are the Ca resonances and black 
peaks are the C~ resonances of residues i and i-1. Peaks in the CBCACONH strips are 
the ca and c~ ofresidue i-1. 
Chemical shift assignments were checked against assignments published by 
Chiliveri et al. (BMRB databank accession No. 17703) [108]. Of the 216 non-proline 
residues in RDE-4, backbone amide resonances were assigned for 197 resonances 
(Figure 2.12). The residues N78, E79, V98, E111, F114, T141, S215, L227, M228, 
1236, S241, M244, V245, V247, 1248, E249, N250, L251, and E252 could not be 
assigned either because the of extensive peak overlapping in the triple resonance 
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experiments or because there were no correlating peaks in the triple resonance 
data. It is possible that the presence of µs-ms timescale dynamics resulted in peak 
broadening. The pro line residues were not assigned since. pro lines lack an amide 
and as a result do not provide signal in the 1H-15N HSQC spectrum. The 10 proline 
residues include 30, 44, 60, 68, 116, 155, 161, 162, 166, and 186. The assigned 
backbone 1 HN and lSN as well as Ca and C~ resonance assignments are listed in Table 
2.1. 
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Figure 2.12: NMR peak assignments of the 
dsRBDs of RDE-4 shown on A) an 1sN-HSQC and 
B) expansion of the boxed central region of the 
spectrum. 
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Table 2.1: Chemical shift assignments of backbone lHN and lSN as well as Ca and C~ 
resonances (ppm) of RDE-4 dsRBDs in 30 mM Tris HCl (pH 8), 250 mM NaCl, 5 mM BME, 5% 
glycerol, 10% D20 at 25°C ('na' denotes assignments that could not be made due to an 
absence of triple resonance data, '?' means resonance data is inconclusive). Residues with 
inconclusive Ca and C~ triple resonance data were assigned based on comparisons with 
chemical shift assignments made by Chiliveri et al. [108]. 
Residue tsN (ppm) tHN (ppm) C0 (ppm) ell (ppm) 
K28 121.353 8.303 56.200 32.780 
T29 117.568 8.163 59.890 69.480 
P30 ---- ---- 63.360 32.390 
R31 121.221 8.409 55.700 30.900 
N32 119.387 8.418 53.260 38.970 
R33 121.515 8.358 56.530 29.830 
T34 114.604 8.273 61.940 69.880 
035 122.456 8.383 55.770 41.020 
L36 124.889 8.413 ? ? 
E37 117.277 8.055 ? ? 
M38 115.169 7.884 ? ? 
F39 122.352 8.143 ? ? 
L40 113.086 8.062 56.090 ? 
K41 116.239 7.081 56.290 32.980 
K42 121.160 7.693 ? ? 
T43 130.442 7.124 58.770 68.430 
P44 ---- ---- 66.370 32.400 
L45 115.958 8.552 58.190 42.930 
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M46 118.465 7.665 59.350 34.480 
V47 118.163 7.915 60.690 ? 
L48 119.821 8.244 58.420 42.830 
E49 118.277 9.022 60.770 29.810 
E50 118.812 8.759 ? ? 
A51 121.449 7.777 55.280 19.230 
A52 120.005 8.799 56.280 18.740 
K53 115.860 7.627 59.780 32.920 
A54 119.742 7.990 55.210 19.560 
V55 115.641 8.729 64.520 ? 
Y56 113.721 6.850 ? 39.52? 
Q57 115.851 7.617 59.730 ? 
K58 115.270 7.545 54.750 36.980 
T59 111.180 7.941 58.810 69.480 
P60 ---- ---- 62.940 30.380 
T61 118.630 8.290 61.870 70.350 
W62 124.592 8.587 55.280 32.930 
G63 111.903 9.559 44.760 ----
T64 119.835 8.663 62.880 71.030 
V65 127.821 8.804 61.950 35.420 
E66 127.751 8.767 56.310 29.880 
L67 126.898 8.123 52.300 41.560 
P68 ---- ---- 65.860 31.330 
E69 111.586 7.936 55.730 29.890 
G70 130.949 7.335 45.820 ----
F71 118.737 8.787 57.450 44.110 
E72 121.223 9.235 55.210 33.320 
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M73 127.653 9.584 52.160 32.910 
T74 120.895 9.587 62.860 69.990 
L75 131.240 9.081 53.220 44.160 
176 125.587 8.499 60.310 41.550 
L77 123.784 8.030 55.230 38.720 
N78 na na ---- ----
E79 ? ? ? ? 
180 122.527 7.360 61.320 39.180 
T81 123.255 7.960 60.960 70.970 
V82 119.509 9.050 59.250 36.510 
K83 117.402 8.323 54.750 37.03? 
G84 128.889 8.853 44.620 ----
Q85 122.387 8.653 54.230 31.900 
A86 121.718 8.587 51.780 22.240 
T87 109.014 8.443 ? ? 
S88 111.549 7.445 55.480 66.450 
K89 124.873 8.646 60.900 31.850 
K90 117.750 8.396 ? ? 
A91 119.742 7.487 54.330 18.850 
A92 122.863 8.118 55.160 18.630 
R93 117.271 8.098 59.840 29.370 
Q94 116.678 7.547 58.810 27.820 
K95 117.623 8.126 ? ? 
A96 121.619 8.336 ? ? 
A97 119.285 8.408 ? ? 
V98 na na ---- ----
E99 118.297 7.880 58.850 28.800 
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YlOO 121.229 8.683 62.370 38.960 
LlOl 116.994 8.576 ? ? 
R102 117.354 8.521 60.890 ? 
K103 120.191 7.741 58.230 31.320 
V104 119.147 8.014 ? ? 
V105 119.156 7.780 66.320 ? 
E106 121.427 8.049 ? ? 
K107 115.289 7.841 56.210 32.380 
G108 130.162 7.999 46.550 ----
K109 117.091 7.882 55.240 33.450 
HllO 119.005 8.643 61.360 30.840 
E111 na na ---- ----
1112 119.103 7.205 62.43? 37.49? 
F113 116.199 6.941 ? ? 
F114 ? ? 57.990? 35.420? 
1115 120.451 7.696 57.810 38.990 
P116 --- ---- 62.410 31.610 
G117 131.057 8.161 45.150 ----
T118 120.381 9.132 64.36? 69.00? 
T119 109.324 7.371 58.750 72.810 
K120 121.179 8.997 60.230 32.380 
E121 116.838 8.628 60.830 28.780 
E122 121.076 7.856 59.080 30.900 
A123 121.729 7.782 55.220 17.680 
L124 116.681 8.445 58.240 40.940 
S125 115.352 7.842 ? ? 
N126 121.952 8.190 ? ? 
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1127 121.520 8.251 ? ? 
0128 120.763 8.404 ? ? 
Q129 116.865 7.859 59.290 29.770 
1130 110.557 7.478 63.300 38.910 
S131 117.750 7.925 60.520 63.520 
0132 120.901 8.381 55.24? 40.95? 
K133 119.842 7.839 56.800 32.710 
Al34 122.967 8.060 52.830 18.930 
E135 119.361 8.151 56.960 30.040 
E136 121.007 8.396 ? ? 
Ll37 122.001 8.151 55.24? 42.11? 
K138 121.895 8.165 56.650 32.890 
R139 122.058 8.305 56.270 32.860 
S140 117.115 8.448 58.320 63.910 
T141 na na ---- ----
S142 117.305 8.248 ? ? 
0143 121.944 8.359 54.120 41.100 
A144 123.663 8.089 52.680 19.300 
V145 119.445 8.053 62.570 32.770 
Q146 123.837 8.409 55.780 29.840 
0147 121.942 8.362 54.340 41.250 
N148 118.911 8.354 53.350 39.250 
0149 121.515 8.291 54.230 41.100 
N150 118.500 8.258 53.090 39.250 
0151 121.070 8.362 54.790 41.130 
0152 120.638 8.262 56.692 32.224 
S153 114.751 8.276 58.210 63.680 
88 
1154 123.589 7.851 59.470 ? 
P155 ---- ---- ? ? 
T156 122.202 8.628 ? ? 
S157 117.616 8.292 58.590 63.920 
A158 125.839 8.274 19.270 52.720 
E159 115.949 7.714 ? ? 
F160 123.691 9.203 57.150 38.540 
P161 ---- ---- ? ? 
P162 ---- ---- 63.830 31.510 
G163 111.144 8.643 45.080 ----
1164 121.888 7.642 57.190 34.920 
S165 121.440 8.721 55.290 63.950 
P166 ---- ---- 62.350 32.930 
T167 128.900 7.505 60.950 68.420 
E168 123.645 6.490 55.290 29.840 
N169 122.246 8.783 50.630 35.950 
W170 128.182 8.834 60.340 28.880 
V171 119.004 7.508 65.910 32.480 
G172 109.292 7.866 47.610 ----
K173 123.071 8.044 59.400 31.420 
L174 121.535 8.688 57.770 42.040 
Q175 120.698 8.127 59.260 27.840 
E176 120.926 8.417 59.860 29.420 
K177 120.565 8.285 59.340 32.310 
S178 115.058 8.480 62.380 ? 
Q179 120.600 7.808 58.250 28.430 
K180 120.277 8.544 59.270 32.890 
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S181 111.992 8.054 58.790 63.870 
K182 117.127 7.626 57.280 28.810 
L183 118.452 8.345 ? ? 
Q184 120.946 8.106 ? ? 
A185 125.226 8.113 50.710 17.650 
P186 ---- ---- ? ? 
1187 120.226 8.116 ? ? 
Y188 123.058 8.727 56.730 41.220 
E189 122.341 8.991 55.200 33.930 
0190 120.912 8.792 52.710 45.610 
S191 114.137 8.886 57.860 65.600 
K192 121.713 8.521 54.760 35.350 
N193 124.954 8.582 52.670 39.550 
E194 125.205 9.028 58.310 29.890 
R195 118.180 8.284 58.280 30.280 
T196 130.356 7.604 61.320 69.870 
E197 117.488 7.929 57.270 27.280 
R198 116.438 7.345 54.730 33.360 
F199 118.923 8.745 58.250 41.950 
L200 121.824 8.755 54.720 41.570 
V201 123.691 9.135 60.830 33.950 
1202 126.570 8.962 59.300 40.460 
C203 130.269 9.256 57.160 28.820 
T204 123.892 8.838 61.350 69.940 
M205 126.651 8.715 56.260 34.860 
C206 121.529 9.288 60.390 25.790 
N207 112.088 8.819 54.340 37.970 
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Q208 118.941 8.047 54.250 31.510 
K209 119.359 7.883 55.170 ? 
T210 110.457 8.833 60.260 ? 
R211 119.272 8.575 57.570 ? 
G212 111.951 9.030 ? ----
1213 122.648 8.171 ? ? 
R214 120.189 8.575 52.220 35.950 
S215 na na ---- ----
K216 117.197 7.613 54.390 34.320 
K217 128.829 8.353 ? ? 
K218 116.526 8.711 59.320 32.260 
0219 118.814 6.600 56.300 40.900 
A220 123.159 8.020 55.780 18.920 
K221 118.050 8.268 59.330 33.040 
N222 117.392 7.817 56.150 39.460 
L223 119.387 8.344 57.210 ? 
A224 121.773 8.325 56.040 18.060 
A225 119.435 8.566 54.710 18.750 
W226 128.109 9.793 ? ? 
L227 na na ---- ----
M228 na na ---- ----
W229 122.508 9.052 61.450 28.790 
K230 119.168 8.584 57.380 30.850 
A231 121.322 7.960 54.240 17.690 
L232 117.549 8.163 ? ? 
E233 120.092 7.894 58.670 30.190 
0234 116.718 8.196 ? ? 
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G235 110.369 7.438 45.090 ----
1236 na na ---- ----
E237 122.522 9.244 ? ? 
S238 116.555 7.916 60.380 62.920 
L239 121.439 7.574 55.840 41.570 
E240 118.897 7.765 58.870 34.36? 
S241 ? ? ? ? 
Y242 120.800 7.749 56.35? 35.27? 
0243 121.169 8.297 54.650 41.080 
M244 ? ? ? ? 
V245 ? ? ? ? 
D246 118.565 8.231 ? ? 
V247 na na ---- ----
1248 na na ---- ----
E249 na na ---- ----
N250 na na ---- ----
L251 na na ---- ----
E252 na na ---- ----
E253 126.920 7.897 ? ? 
Based on the CO, Ca, and C~ assigned resonances, the secondary structural 
elements of RDE-4 were analyzed to provide a consensus chemical shift index (CSI) 
of the protein (Figure 2.13). The resulting CSI shows a complete a~~~a motif for 
dsRBDl (residues 33-104) and partial a~~~a motif for dsRBD2 (residues 170-232) 
that is lacking the last helix of the motif. A partial motif is seen for the dsRBD2 
92 
because the majority of residues that could not be assigned belonged to the amino 
acids located in that expected helix region of dsRBD2. Nonetheless, the CSI data for 
the assigned resonances of RDE-4 is consistent with the consensus that is 
characteristic for protein domains that bind to dsRNA and reinforces that RDE-4 
assignments made are reasonable. Furthermore, the CSI data shows a structured 
linker region between the dsRBD domains that contains a-helices. The indication of 
this structured region reinforces that the linker sequence is necessary for RDE-4 
expression and possibly for the binding function of the protein. 
RDE-4 Chemical Shift Index 
218 228 238 248 
Residue Number 
Figure 2.13: The consensus chemical shift index of the dual dsRBD region of RDE-4 
derived from the assigned CO, Ca, and Cf} resonances with respect to residue number. 
Helices = -1, loops = 0 and sheets = 1. 
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2.3.4 SAXSAnalysis ofRDE-4 dsRBDs 
Small angle X-ray scattering (SAXS) was performed on RDE-4 dsRBDs to 
obtain structural information about the shape and size of this protein. Unlike 
crystallography, a crystalline sample is not needed for SAXS experiments, which is a 
desirable feature since the RDE-4 protein proved difficult to crystallize. The SAXS 
data obtained of the RDE-4 protein effectively complements the NMR-based 
structural studies presented. 
SAXS data on RDE-4 dsRBDs reveals that the protein, containing two 
domains separated by a linker region, has a football-like shape opposed to being 
dumbbell-like (Figure 2.14). This implies that a flexible linker does not separate the 
two domains and the two domains do not interact with one another, thus forming a 
continuous interface. This single structured unit would enable RDE-4 to bind long 
RNA molecules that fit the entire binding site, but not RNA molecules that are 
shorter than the length of the binding surface. This also implies that important 
RNA-interacting residues exist at both ends of the binding site. 
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Figure 2.14: SAXS 3D structural map of RDE-4 dsRBDs protein represented as a) 
points in space and b) a continuous surface. Both maps suggest that the dual dsRBD 
of RDE-4 has a football-like structure. The data implies that a continuous surface 
exists where the two domains do not interact with one another. 
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An ab initio calculation of the structural envelope of the RDE-4 protein 
overlays very well with a derived model of the RDE-4 protein that is based on the 
structure of the DGCR8 protein (Figure 2.15) [102]. The largest deviation between 
the model and SAXS-derived shape occurs at residues 81-104. Here, RDE-4 is 
expected to form a long loop ending with a short four-residue helix. This difference 
is insignificant and occurs because there are no restraints on this unstructured loop. 
Future models of RDE-4 would be refined against the SAXS-derived molecular shape 
and should accommodate this loop within the structural envelope. 
Figure 2.15: Overlay of a structural model and the SAXS-derived structural 
envelope of the dual dsRBD-containing RDE-4 protein. Shown in the green cartoon 
is the structure of RDE-4 modelled on the DGCR8 structure [PDB ID: 2YT4] [102]. In 
red is the ab initio determined structural envelope of RDE-4. Overall, there is a fair 
agreement between the model and the experimentally derived shape. This 
structural overlay demonstrates that RDE-4 likely forms a single structural entity as 
opposed to being two separate nodes connected by a linker region. 
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2.3.5 Crystallization of RDE-4 dsRBDs 
Crystals of the RDE-4 dsRBDs proved to yield promising r~sults under 
optimized crystal screen conditions of 0.2 M sodium citrate, 0.1 M Tris HCl (pH 6.2), 
20% PEG 400 and 0.2 M sodium citrate, 0.1 M Tris HCl (pH 6.8), 25% PEG 400. The 
crystal grown at pH 6.2 with 20% PEG 400 had measured dimensions of 2.2 mm 
(length) x 2.2 mm (width) (Figure 2.16 A). The crystal grown at pH 6.8 with 25% 
PEG 400 obtained had measured dimensions of 1.2 mm (length) x 1.4 mm (width) 
(Figure 2.16 B). Unfortunately, diffraction of these crystals showed no protein 
diffraction patterns, but instead evidence of salt peaks. 
A) B) 
Figure 2.16: Crystallization of the RDE-4 dsRBDs protein grown by hanging drop 
method. The protein is 0.5 mM in a buffer of 20mM Tris HCl (pH 7.0), 400mM NaCl, 
0.SmM EDTA. Screen conditions of A) 0.2M sodium citrate, O.lM Tris HCl (pH 6.2), 
20% PEG400 and B) 0.2M sodium citrate, O.lM Tris HCl (pH 6.8), 25% PEG 400. 
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It must be noted that it was unknown when both crystals were formed 
because the crystal screen from which both crystals originated were not checked 
previously for more than a year. Since crystal formation of the RDE-4 dsRBDs 
occurred in the presence of polyethylene glycol (PEG), new screens using fresh 
protein (llmg/mL) were set up using Qiagen NeXtal PEGs I Suite and Qiagen NeXtal 
PEGs II Suite that contained several molecular weights of PEG in various 
combinations. In addition, screens were assembled using the Qiagen NeXtal JCSG+ 
Suite to check the crystallization possibilities with other commonly tested 
precipitants. And finally, crystal screens were set up using the Qiagen NeXtal MPDs 
Suite to determine if the organic precipitant 2-methyl-2,4-pentandiol (MPD) would 
encourage protein crystallization. After almost a year, no crystals were evident in 
any of these screens. On average, an optimized crystal diffracts at 5.0 A. For 
publications, diffraction at 4.0 A is most often required, but at this range only 
information about protein folds with resolution of only some side-chains is possible. 
At 3.5 A side-chain positions can be resolved with confidence. For the purposes of 
the RDE-4 project, resolution of at least 3.0 A would be necessary to make 
conclusions about specific interactions and biological function. 
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2.3.6 Binding Studies of the Dual dsRBD Region ofRDE-4 to Long dsRNA by Gel 
Shift Assay 
To investigate the nucleic acid binding properties of the dual dsRBD region of 
RDE-4, gel mobility shift assays were performed with purified RDE-4 and an in-
house synthesized 83 nucleotide RNA substrate (83mer) composed of 39 Watson-
Crick base pairs and a GAAA tetraloop (Figure 2.17). Tetraloops assist in initiating 
the RNA folding process as well as by providing sites for RNA tertiary contacts and 
for protein folding. The addition of a GAAA tetraloop has been found to significantly 
increase RNA folding stability, therefore an RNA hairpin without a GAAA tetraloop 
may affect protein binding due to the possibility of decreased stability of the RNA 
structure. For these reasons, binding studies were performed using a 83mer RNA 
containing a GAAA tetraloop that was synthesized from a 100mer DNA template 
(Figure 2 .18). 
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(a) 
A so 60 . 70 so 3 • 
A UUCGUCGAAUCCUCGGCUU AAAGCC UGCCUAAGUUCCG C 
I II I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I I I 
A AAGCAGCUUAGGAGCCGAA UUUCGGACAGAUUCAAGGC GG 
G 40 30 20 1 o s' 
(b) 
Figure 2.17: (a) Sequence and putative secondary structure of the 83 nucleotide 
RNA molecule (83mer) used in these studies. The molecule is composed of 39 
Watson-Crick base pairs and a GAAA tetraloop. (b) Model of the structure of the 
83mer generated by MC-Sym. This structure was generated with the assumption 
that the molecule would form a standard A-form helix and have the canonical 
tetraloop structure. 
100 
100 base pair DNA template 
83mer RNA 
55 nt xylene/cyanol dye 
Figure 2.18: 20% denaturing polyacrylamide gel of 83mer RNA (lane 2) product 
transcribed from a 100 base pair DNA template (lane 3). 
Shifts were observed on an 8% native polyacrylamide gel (19:1, 
acrylamide:bisacrylamide) for complexes with 0.75X, 1X, 2X and 3X protein excess, 
indicating that the dual dsRBD region of RDE-4 has an affinity for this long dsRNA 
and that RNA binding is significant with higher amounts of protein (Figure 2.19). 
Conversely, increasing the concentration of RNA rather than protein does not show 
binding. These data suggests that multiple RDE-4 molecules bind to an RNA 
substrate with positive cooperativity, thereby increasing the binding density and the 
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overall size of the complex, resulting in decreased mobility. The indication of 
binding events occurring between the RDE-4 dsRBDs and the RNA oligo makes it 
possible to identify the length and composition of RNA necessary for conducting 
structural studies of the RDE-4:RNA interaction by NMR methods. 
[RDE-4 dsRBDs] (µM) 
Free 
RNA 0.25X 0.5X 0.75X 1X 2X 3X 
Bound 
Free 
Figure 2.19: Gel mobility shift analyses of RDE-4 and 83mer RNA on an 8% native 
polyacrylamide gel. Bands corresponding to bound and free RNA are labelled. 
Increasing concentrations of RDE-4 added to 83mer RNA shows significant band 
shifting, indicating that protein-RNA complex formation occurs at high protein 
concentrations. 
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2.3.7 Binding Studies of the Dual dsRBD Region ofRDE-4 to Long dsRNA by 
NMR and ITC Techniques 
To identify residues from the dual dsRBD of RDE-4 that are important for 
RNA binding, chemical shift changes between the RDE-4 protein and RDE-4 
protein:83mer RNA complex was completed using an 15N-HSQC NMR experiment. 
This type of 20 experiment is a standard NMR experiment that shows all H-N 
correlations. These correlations are mainly backbone amide groups, however 
asparagine [109] and glutamine (Gin) side-chain NcS-HcS2/N£-H£2 groups, as well as 
tryptophan (Trp) residue side-chain Ne-He groups are also seen. The Ne-He peaks 
from arginine (Arg) residues are also visible, but are most often seen as negative 
peaks that are aliased/folded because they are at a chemical shift outside the 
recorded regions. 
1sN-HSQC spectra of the RDE-4 protein and RDE-4 protein:83mer complex 
showed. well dispersed peaks indicative of a well-folded protein and protein 
complex. The bound spectrum is clearly different, indicating that binding is 
occurring. From a superposition of the two spectra, a large number of peaks 
disappear, some peaks shift in chemical shift, and some remain unchanged (Figure 
2.20). 
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Figure 2.20: Overlay of RDE-4:83mer RNA (red) and RDE-4 protein (black) spectra. 
Most likely, the residues that disappear lie directly at the binding site, those 
that shift are close to the binding site and those that remain unchanged are far 
removed from the binding site. Dynamics at the binding site may result in the 
observed signal loss because of movement of the RNA in the protein-binding site, or 
due to movement of the protein along the RNA helix. Furthermore, intermediate 
exchange as a result of RDE-4 binding to long RNA with an intermediate affinity may 
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cause peaks to disappear. Since the peaks disappear in the dual dsRBD, which is 
essentially the entire region of the protein studied, these results suggest that there 
is a significant global change between the free and bound structures and not just the 
residues on the binding face are affected. Furthermore, the binding does not 
stabilize the floppy terminus ends of the protein. 
An ITC study of RDE-4 titrations into the 83mer RNA show binding is 
determined to occur at micromolar affinity of Kd1 = 2.6 µM. This result is consistent 
with binding being in the intermediate exchange rate on the NMR timescale. 
Intermediate exchange leads to the line broadening that is seen in the NMR 
experiments. Furthermore, this result is in agreement with the micromolar binding 
affinity reported by Bass et al. [110]. A two-site binding model is used to fit the data 
to show that there is a second binding event occurring upon complex formation 
where a second protein molecule binds the RNA, however this binding is much 
weaker at approximately Kd2 = 0.3 mM (Figure 2.21). This research presents the first 
report of an affinity value for the second binding site known to date. 
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Figure 2.21: ITC profile of RDE-4 binding to the 83mer RNA. A two-site binding 
model shows that binding of RDE-4 dsRBDs to long dsRNA occurs via more than one 
protein molecule and that binding affinity is in the micromolar range. 
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2.4 CONCLUSIONS 
For years scientists have studied proteins, such as transcription factors, that 
regulate gene activity. Now, the use of RNA through the RNAi process is recognized 
as a key approach for gene regulation. RNAi has expanded dramatically since its 
discovery, however, the intricacies of this natural process still remains largely 
unknown. By understanding the mechanistic details and the biomolecules involved 
in this process, the ability of RNAi to knock down genes that are responsible for the 
activity of diseases can essentially be accomplished easily and quickly. As a result, 
continued research into RNAi will allow this process to become a powerful tool for 
medical therapies. 
RDE-4 in C. elegans served as a useful model for studying how double 
stranded RNA binding proteins that bind to dsRNA molecules are critical for RNAi 
cellular processes. The near complete backbone chemical shift assignments of the 
RDE-4 construct confirmed characteristic protein domains that bind to dsRNA. 
RDE-4 preferentially binds to long dsRNA rather than short dsRNA molecules [96]. 
For this binding event to occur, the two binding domains in the RDE-4 protein do 
not interact with one another, but instead forms a continuous interface onto which 
the long dsRNA can interact. The results presented here suggest that important 
residues exist at both ends of the binding site. The location of these important 
residues facilitate binding to long RNA molecules and not to short RNA molecules 
(Figure 2.22), which affords the RDE-4 protein the ability to bind to the long target 
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dsRNA and not to the short siRNA product. During binding, multiple RDE-4 
molecules cooperatively bind to a non-sequence specific RNA substrate with 
micromolar affinity. This protein-RNA interaction causes a significant global change 
of the protein structure and not just the residues on the binding face are affected. 
1. Binding to long RNA 
2. No Binding to short RNA 
Target 
dsRNA 
Figure 2.22: Proposed mechanism for the selective binding of RDE-4 to long, but 
not short RNA. This hypothesis proposes that the two dsRBDs in RDE-4 (brown) 
form one long binding surface with critical residues located at either end (shown by 
asterisks; *). In this model, long dsRNA can interact with the necessary regions of 
both dsRBDs (1). In contrast, short dsRNA molecules cannot interact with all the 
important residues on the binding surface and therefore does not bind (2). 
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2.5 FUTURE WORK 
The future work of this research project aims to expand upon these studies 
by continuing to investigate the critical residues at the end of the binding site that 
are needed for a long RNA molecule to interact and for productive binding to occur. 
This information will allow for a plausible binding mechanism to be established that 
will explain why RDE-4 binds to long RNA rather than short RNA molecules. To 
accomplish this, mutagenesis experiments of the terminal residues of the dual 
dsRBD region of RDE-4 will allow for a better understanding of the structural basis 
for this binding specificity. To investigate this binding specificity further, additional 
NMR studies and binding studies of RDE-4 with a range of RNA molecules with 
varying lengths and GC content will be useful for studying binding affinity. 
Furthermore, it may be possible that sequence plays a role in RNA recognition by 
RDE-4, potentially through RNA duplex stability. The stability of these RNA 
molecules is expected to be different and can be measured by UV-monitored 
thermal melting methods. Additional aspects to be addressed include explaining 
how RDE-4 interacts with DCR-1 and determining the structure of the RDE-4 C-
terminal domain in order to understand its function. 
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CHAPTER3 
AN INVESTIGATION OF THE DYNAMICS OF DIHYDROFOLATE REDUCT ASE 
UPON INHIBITOR BINDING 
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3.0 DIHYDROFOLATE REDUCTASE 
The enzyme DHFR is an important cancer and rheumatoid arthritis 
therapeutic target. DHFR regulates 5,6,7,8-tetrahydrofolate (THF) production in 
cells by using the cofactor nicotinamide adenosine dinucleotide phosphate (NADPH) 
to catalyze the reduction of 7,8-dihydrofolate (DHF) to (THF) via a cycle of 
conformational changes [111]. The THF product is essential for the synthesis of 
nucleic acid precursors and amino acids. Therefore, the inhibition of DHFR can limit 
the growth of rapidly dividing cells in cancers as well as limit this enzyme from 
preventing amino acid metabolism that leads to rheumatoid arthritis. Research of 
potential inhibitors of DHFR is of particular interest for the development of anti-
cancer and anti-arthritis drugs such as methotrexate [112]. 
The three-dimensional structure of DHFR (159 amino acid) consists of eight-
strand beta sheets that are connected by four alpha helices along with several 
flexible loops [113]. The enzyme can be divided into two subdomains: (1) the 
cofactor-binding domain (residues 38-88) that binds NADPH through the 
adenosine-binding loop (residues 67 to 69) and, (2) the major catalytic subdomain. 
The major catalytic subdomain is located in the active site and binds the substrate 
via an active-site loop called the Met20 loop (residues 9 to 24), FG loop (residues 
116 to 132), and GH loop (residues 142 to 150), all of which participate in the 
catalysis to some extent (Figure 3.1) [114]. 
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Figure 3.1: Three-dimensional structure of DHFR (PDB ID: 2ANQ) containing 8 
strand beta sheets and 4 alpha helices connected by flexible loops including the 
Met20 loop (red), FG loop (blue), GH loop (purple), and adenosine-binding loop 
(orange). All other resides are colored green. 
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During the catalytic cycle, the enzyme (E) adopts either a "closed" 
conformation or an "occluded" conformation, depending on the intermediate 
formed (Figure 3.2) [114]. 
Figure 3.2: Conformations of DHFR during the catalytic cycle: A. closed, and B. 
occluded. The polypeptide backbone that surrounds the active site and adenosine-
binding loop (blue and green), substrate (yellow) and cofactor (pink) are indicated 
[115]. 
In the binary haloenzyme, E:NADPH, the Met20 loop assumes a closed 
conformation that allows for close packing of the nicotinamide ring of NADPH 
(Figure 3.3) [111]. Water molecules near the active site donate a proton to NS of 
DHF (Figure 3.3). 
113 
NADPH 
OH 
Figure 3.3: Chemical structures of NADPH and DHF. 
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Subsequent binding of the DHF substrate to the active site permits a hydride 
transfer from NADPH cofactor to the C6 atom of the pterin ring in the DHF molecule 
to yield the THF product and oxidation of NADPH to NADP+ (Figure 3.4) [116]. As a 
result of this hydride transfer, the Met20 loop of the ternary complex, E:NADP+:THF, 
adopts an occluded conformation that sterically prevents the nicotinamide ring 
from binding to the active site, causing the nicotinamide ring to be positioned 
outside of the substrate binding pocket [114]. The occluded conformation is made 
possible by the protruding sidechain of residue M16 of the Met20 loop into the 
active, as well as the disruption of the hydrogen-bonding network between the 
Met20 loop and the FG loop, and the formation of new hydrogen-bonding between 
the Met20 loop and the GH loop [114]. Replenishment of NADPH to the active site 
releases the THF product (rate-limiting step) and allows for the catalytic cycle to 
repeat. Studies of the kinetic characterization of intermediates show that DHFR 
proceeds through a conformational catalytic cycle involving five intermediates: 
E:NADPH, E:NADPH:DHF (Michaelis complex), E:NADP+:THF, E:THF, E:NADPH:THF 
[111]. 
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Figure 3.4: Catalytic cycle of DHFR. The boxed molecules indicate the various 
complexes of DHFR. 
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The active site structure of DHFR is maintained by the Met20 loops through 
hydrogen bonding with the F-G and G-H loops (Figure 3.5) [117]. It is this hydrogen-
bonding network that determines the conformation of the Met20 loop and 
intervenes ligand binding. Various X-ray crystal structures of DHFR show that the 
Met20 loop exists in an occluded, closed, open conformations, and disordered 
conformations. However, the occluded and closed conformations occur most often 
[117]. Furthermore, NMR spectroscopy data demonstrate that only the closed and 
occluded conformations exist in solution with no evidence of the open conformation 
being present [118]. The occluded conformation is seen in the DHFR:NADP+:THF, 
DHFR:THF, and DHFR:NADPH:THF complexes. The closed conformation is apparent 
in the DHFR:NADPH:DHF and DHFR:NADPH complexes [119]. 
Many studies of E. coli DHFR have shown that dynamics in the protein 
structure are important for function and catalysis [120]. A primary method for 
studying these dynamic motions and relating them to protein function and catalysis 
is by NMR relaxation techniques [111, 115, 121-123]. Previous studies on DHFR 
have shown that conformational changes in the active site loop are critical in 
mediating cofactor and substrate binding and product release. Further evidence of 
conformational differences in DHFR complexes arise from backbone dynamics 
obtained from 15N NMR spin relaxation data on the closed DHFR:NADP+:folate 
complex and occluded complexes. The Met20 loop and residues 119-123 in the F-G 
loop experience considerable motion and rotational freedom in the occluded 
complexes but become significantly diminished in the closed DHFR:NADP+:folate 
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complex [122]. Moreover, it has been reported that replacing residues 16-19 of the 
Met20 loop with a single glycine resulted in a 500-fold reduction in hydride transfer 
without affecting the Michealis constant for DHF and NADPH [124]. This result 
emphasizes the importance of the Met20 loop in the catalytic cycle of DHFR. For 
these reasons, understanding how the dynamics of DHFR is affected when bound to 
an inhibitor and how the altered dynamics affects the protein structure and function 
is important for therapeutic development. 
NADP 
FGloop 
Figure 3.5: Hydrogen bonding network between the Met20, F-G, and G-H loops. 
The closed conformation of the Met20 loop is indicated in red and the occluded 
conformation of the Met20 loop is indicated in green [118]. 
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3.1 RESEARCH GOALS 
DHFR is one of the most studied enzymes to date, with its structure, function, 
and dynamics being extensively investigated. However, less has been reported on 
how inhibitors alter DHFR dynamics [114]. Establishing small molecules that act as 
antifolates against DHFR and understanding how these inhibitors affect the 
dynamics of DHFR is highly beneficial for drug discovery [112]. Most compounds 
known to be competitive inhibitors of E. coli DHFR are either 2,4-
diaminoquinazoline or 2,4-diaminopyrimidine derivatives [114]. However, a recent 
inhibitor, 1,4-Bis-{[N-(1-imino-1-guanidino-methyl)]sulfanylmethyl}-3,6-dimethyl-
benzene (from here on referred to as compound 1) (Figure 3.6), has been identified 
by us in collaboration with Dr. Michael Organ, that does not contain the usual 
diaminoheterocycle known to be required for DHFR inhibition but instead contains 
two isothiourea groups that allows for new therapeutic possibilities [116]. This 
novel inhibitor binds DHFR:NADPH with a Kd of 13 ± 5 nM, has positive binding 
cooperativity with the NADPH cofactor, and binds to DHFR 285-fold tighter in the 
presence of the NADPH cofactor compared to in its absence [116]. The affinity of 
DHFR:NADPH for 1 is comparable with known inhibitors of DHFR such as 
methotrexate (MTX) (Figure 3.6), whose Kd is from 10-8 M to less than 10-11 M. 
Inhibitor 1 is particularly unusual because it interacts with the Met20 loop of DHFR, 
a region other DHFR inhibitors have not been seen to interact with. 
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1 
~N-< -N O~ 
N- OH 
OH 
NH2 
0 
MTX 
Figure 3.6: Chemical structure of inhibitors 1 and MTX respectively. 
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The aim of this study was to better understand the enzyme function of E. coli 
DHFR by comparing the dynamics of the free enzyme and when bound to the 
recently discovered inhibitor 1. 1H-15N NMR relaxation methods was used to 
investigate the dynamics of E. coli DHFR by comparing the change in molecular 
motions that occur between free DHFR:NADPH and when bound to inhibitor 1. 
In addition, ITC was used to investigate the thermodynamics of DHFR upon 
binding to inhibitor 1 and the established inhibitor MTX. To achieve this goal, 
enthalpies of binding were determined by ITC over a range of temperatures, 
allowing for estimates of heat capacity changes. The purpose of this data was to 
provide an understanding of the energetic contributions to the stability of the 
protein-inhibitor complexes of DHFR that is currently not known. More specifically, 
this part of the project aims to determine if the known X-ray structure is the same 
structure that binds inhibitor 1 and MTX. This study was important as it can lead to 
the development of new and better inhibitors of DHFR with different modes of 
action. 
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3.2 MATERIALS AND METHODS 
3.2.t 15N Minimal Media Cell Preparation 
BL21 (pLysS) E. coli cells were transformed with a pFW117.1 plasmid 
containing the folA gene coding for E. coli DHFR. Cells were grown at 37°C in M9 
minimal media containing 1 g/L of 99% (15NH4)2S04 (Cambridge Isotope 
Laboratories, Inc.). Over expression was induced with 1 mM IPTG when the cells 
reached OD6oo = 0.6-0. 7 and subsequently allowed to grow for 3 hours. The cells 
were harvested by centrifugation and suspended in buffer (20 mM Tris (pH 6.2), 0.5 
mM EDTA, 0.5 mM DTT, 0.02% (w/v) NaN3). 
3.2.2 Protein Purification 
Cells were lysed by sonication, centrifuged, and the lysate filtered using a 
0.45 µm filter followed by a 0.2 µm filter. The lysate was loaded onto a quaternary 
(Q) anion-exchange column (GE Healthcare) pre-equilibrated with buffer (20 mM 
Tris (pH 6.2), 0.5 mM EDTA, 0.5 mM DTT, 0.02% (w/v) NaN3) and eluted at 0.4 M 
NaCl over a NaCl gradient of 0.1-1.0 M. Fractions containing 1H-15N DHFR were 
pooled and concentrated using 5,000 MWCO concentrators (Amicon) and exchanged 
into buffer (SO mM sodium phosphate (pH 7.0), 1 M (NH4)2S04, 0.02% (w/v) NaN3) 
that was also used to pre-equilibrate a hydrophobic interaction column (GE 
Healthcare). The protein was loaded onto the hydrophobic interaction column and 
eluted at 0.5 mM (NH4)2S04 over a 1.0-0.0 M (NH4)2S04 gradient. The fractions 
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containing 1H-15N DHFR were pooled and concentrated to 2 mL, and loaded onto a 
Sephacryl S-100 size exclusion column (GE Healthcare). DHFR was isolated with 100 
mM sodium phosphate (pH 7.0), 150 mM NaCl, 5mM MgClz, 0.5 mM EDTA, and 
0.02% (w /v) NaN3. The fractions containing 1H-15N DHFR were pooled and 
concentrated. The final volume of purified 1H-15N DHFR was 500 µL. 
3.2.3 NMR Sample Preparation 
The final NMR sample contained 3 mM 1H-15N DHFR in NMR buffer (50 mM 
sodium phosphate, 100 mM KCI, 1 mM EDTA, 5 mM DTT, and 0.02% (w/v) NaN3) 
that was deoxygenated by freeze-pump-thaw cycle under vacuum and then purged 
with argon. Subsequently, 10% (v /v) D20, 60 mM NADPH and, when applicable, 4.5 
mM of inhibitor 1 (Maybridge, Trevilett, UK) was added. The samples were placed in 
NMR tubes, purged with argon using a long needle inserted into the sample, and 
sealed with paraffin around the capped tube. 
3.2.4 NMR Spectroscopy - Relaxation Dispersion 
All 1H-15N NMR spectra were acquired at 25°C on a Varian 600 MHz 
spectrometer. Relaxation rates were measured using Ti, Tz, {1H}-15N NOE, and CPMG 
pulse sequences for both the DHFR:NADPH (free) and DHFR:NADPH:1 bound 
complexes. 
Ti values were obtained at time delays -c = 10, 50, 90, 150, 210, 310, 410, and 
510 ms. Tz values were obtained at time delays -c = 10, 30, 50, 70, 90, 110, 130, and 
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150 ms. To test the reliability of the data, a repeat spectrum was recorded at 10 ms 
for both Ti and Tz experiments. To prevent sample heating, recycle delays of 1.5 s 
were used for both T 1 and Tz during data acquisition. {1H}-15N NOE values were 
recorded from spectra in the presence and absence of proton presaturation during 
relaxation period of i; = 3.0 s. 
The constant-time relaxation compensated CPMG dispersion experiments 
had a total relaxation period of 40 ms in all experiments. CPMG spectra were 
recorded with delays i; = 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, and 
34 ms. The effective field strength was modulated by changing the delay time, -r, 
allowing for the CPMG spectra to be collected at a series of 19 2D data sets with 
CPMG field strengths, vcp, of 25, 51, 76, 102, 129, 155, 182, 209, 237, 265, 293, 321, 
350, 379, 409, 439, and 469 Hz, with a repeat experiment performed at vcp = 25 Hz 
and reference spectra obtained by omitting the CPMG period in the pulse sequence 
such that vcp = 0 Hz. 4 scans per FID were recorded. 1H-15N HSQC experiments were 
included before and after each of the four types of relaxation experiments to 
monitor the stability of the NMR sample through the duration of the experiments. 
All spectra were recorded at tH and 15N spectral widths of 9058.0 Hz and 1700.0 Hz 
respectively. Data were acquired at matrices of 1536 by 160 total points. 
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3.2.5 Relaxation Analysis 
NMR data were processed with NMRPipe [125] and visualized with 
NMRDraw [125]. Peak intensities were extracted using the NMRDraw module 
nlinLS. For the standard relaxation experiments Ti, Tz, and {1H}-1SN NOE, the peak 
intensities were converted to Ri, Rz, and {1H}-15N NOE relaxation rates respectively. 
For CPMG experiments, the extracted peak intensities were converted into decay 
rates, Rzeff, for a given CPM G field strength, vcp. The program 'pdbinertia' (developed 
by Dr. A. G. Palmer, Columbia University, 1996) was used to calculate the principle 
moments of inertia for the atoms in the pdb file of E. coli DHFR (Protein Data Bank, 
PDB ID: 2anq) and translate the protein's center of mass so that it is located at the 
origin and rotated, allowing the moments of inertia to be aligned with the Cartesian 
axes. The program 'r2r1_tm' (developed by Dr. A. G. Palmer, Columbia University, 
1996) was used to calculate global and local effective correlation times from the lSN 
relaxation data. From the local diffusions coefficients, the rotational diffusion tensor 
of the protein was calculated using the 'quadratic_diffusion' program. The newly 
generated pdb file corresponding to the proper tensor diffusion model was then 
used an input file for ModelFree 4.15 program using the Lipari and Szabo 'FAST-
Modelfree' graphical user interface program software (Facile Analysis and Statistical 
Testing for Modelfree ). 
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3.2.6 Determining 4Cp of DHFR:NADPH:Inhibitor by ITC 
ITC experiments were performed using a MicroCal VP-ITC instrument. All 
samples were prepared in 50 mM potassium phosphate (pH 6.8), 100 mM KCI, 1 mM 
EDT A, 5 mM OTT. The buffer was purged with Argon and degassed using the 
MicroCal ThermoVac. Titrations were performed by injecting with either 3 
consecutive 8 µL aliquots of ligand solution (inhibitor 1 or MTX) into the ITC cell 
containing DHFR with NADPH over consecutive temperatures of 10°C, 15°C, 20°C, 
25°C, and 30°C. The enthalpy of reaction at each temperature was determined from 
the average of the three enthalpy values obtained that were extrapolated from they-
intercept of the binding isotherm curve. 
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3.3 RESULTS AND DISCUSSION 
3.3.1 Protein Purification 
In order to obtain pure 1H-15 N DHFR, three chromatographic columns were 
employed. Use of an anion-exchange column, followed by a hydrophobic column and 
lastly a size-exclusion column resulted in pure 1H-1SN DHFR (Figure 3.7). 
A) B) 
C) D) 
KDa 
17 
Figure 3.7: Purification scheme for 1H-15N DHFR involved three columns: A) anion 
exchange, B) hydrophobic interaction, and C) size exclusion to yield D) the pure 
protein sample. 1H-15N DHFR (21 KDa) is boxed in red. 
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3.3.2 Chemical Changes of DHFR:NADPH Upon Binding of Inhibitor 1 
The majority of studies interested in investigating the dynamic properties of 
proteins and their alteration upon molecular interaction have been achieved using 
the amide 1sN nucleus that is attached to a 1H nucleus in an isolated two-spin 
system, allowing for easier probing of backbone motions [71]. Prior to the setup of 
any relaxation experiments, a 2D lH_lSN HSQC (heteronuclear single quantum 
coherence) spectrum of 1H-15N DHFR was acquired to ensure that protein was 
detectable in the NMR. Confirmation of detectable protein allowed for addition of 
NADPH cofactor to the sample. The acquired spectrum of DHFR:NADPH showed 
better defined peaks compared to DHFR in the absence of NADPH, suggests that the 
cofactor binding to DHFR provides important conformational stability (Figure 3.8). 
The 1H-15N HSQC experiment is useful for detecting each unique proton attached to 
the nitrogen that is being considered, resulting in a peak in the HSQC spectrum for 
each amino acid along the protein's amide backbone. The HSQC spectrum of the 
binary complex indicated that the expected number of peaks were present for the 
159 residue protein. 
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Figure 3.8: 1H-15N HSQC spectrum of the DHFR:NADPH complex. 
Addition of inhibitor 1 to DHFR:NADPH resulted in a 1H-15N HSQC spectrum 
of the ternary complex (Figure 3.9) that showed chemical shift changes of specific 
residues when compared to the spectrum of the binary complex (Figure 3.10). 
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Figure 3.9: 1H-15N HSQC spectrum of the DHFR:NADPH:1 complex. 
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Figure 3.10: Overlay of DHFR:NADPH:l complex 1H-15N HSQC (red) and 
DHFR:NADPH complex lH_lSN HSQC (black). 
The magnitudes of the chemical shift changes for all residues in the lHN and 
15N dimension for DHFR are listed in Table 3.1 and illustrated in Figures 3.11-3.12. 
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Table 3.1: List of backbone 1HN and 15N chemical shift changes in DHFR complexes 
(DHFR:NADPH and DHFR:NADPH:1). 
Residue DHFR:NADPH DHFR:NADPH DHFR:NADPH:l DHFR:NADPH:l M 1HN (ppm) M 1N (ppm) 
o tHN (ppm) o 15N (ppm) o 1HN (ppm) o 15N (ppm) 
Metl ---- ---- ---- -·-- ---- ----
Ile 2 9.368 124.774 9.419 124.461 -0.051 0.313 
Ser 3 9.318 126.053 9.359 125.939 -0.041 0.114 
Leu4 8.435 121.987 8.586 121.76 -0.151 0.227 
Ile 5 ---- ---- ---- ---- ---- ----
Ala6 8.608 128.925 8.894 105.695 -0.286 23.23 
Ala 7 10.295 128.186 10.195 125.371 0.1 2.815 
Leu 8 9.039 122.613 8.988 121.703 0.051 0.91 
Ala 9 8.492 126.167 8.665 126.053 -0.173 0.114 
VallO 7.574 118.376 7.621 118.461 -0.047 -0.085 
Asp 11 9.089 122.84 9.133 122.897 -0.044 -0.057 
Arg12 8.479 107.77 8.492 107.486 -0.013 0.284 
Val 13 7.097 120.793 7.112 120.679 -0.015 0.114 
Ile 14 ........ ........ ---- ........ ---- ----
Gly 15 7.288 105.552 7.335 105.922 -0.047 -0.37 
Met16 8.677 119.684 8.479 119.542 0.198 0.142 
Glu 17 10.091 130.46 10.195 130.659 -0.104 -0.199 
Asn 18 9.645 114.879 9.398 113.221 0.247 1.658 
Ala 19 ---- ---- ---- ---- ......... ----
Met20 ......... ---- ---- ---- ---- ----
Pro 21 ........ ......... ---- .. ....... .. ...... .. ...... 
Trp 22 7.09 115.732 7.559 116.67 -0.469 -0.938 
Asn 23 8.79 116.926 8.935 117.807 -0.145 -0.881 
Leu 24 ---- ---- ---- ---- ---- ----
Pro25 ........ ---- ........ .. ...... ---- ........ 
Ala26 9.337 121.02 9.403 121.02 -0.066 0 
132 
Asp 27 7.725 117.04 7.568 117.324 0.157 -0.284 
Leu 28 7.543 119.058 7.185 119.058 0.358 0 
Ala 29 ---- ---- ---- ---- ........ ----
Trp 30 7.232 123.153 7.637 124.177 -Q.405 -1.024 
Phe31 ---- ---- ---- ---- ---- ........ 
Lys 32 ---- ---- ........ ---- ---- ----
Arg33 7.832 116.727 7.892 116.528 -0.06 0.199 
Asn 34 7.037 111.524 6.955 111.268 0.082 0.256 
Thr35 7.119 106.775 7.084 106.519 O.Q35 0.256 
Leu 36 7.159 124.489 7.15 123.778 0.009 0.711 
Asn 37 8.319 115.902 8.288 115.021 0.031 0.881 
Lys 38 7.634 119.826 7.738 119.684 -0.104 0.142 
Pro 39 ......... ---- ........... ---- ---- .. ...... 
Val40 8.476 112.092 8.595 112.007 -0.119 0.085 
Ile41 8.423 121.703 8.46 121.447 -0.037 0.256 
Met42 8.957 123.693 9.02 124.177 -0.063 -0.484 
Gly43 8.96 105.666 8.991 107.344 -0.031 -1.678 
Arg44 7.59 118.916 7.568 118.803 0.022 0.113 
His 45 ---- ---- ---- ........ ......... ......... 
Thr46 8.02 121.219 8.237 121.219 -0.217 0 
Trp 47 ........ ---- ......... ---- ---- ----
Glu48 ........ ---- ---- ---- ---- .. ...... 
Ser49 7.769 114.367 7.716 114.452 0.053 -0.085 
Ile 50 ---- ---- ---- ---- ---- ----
Gly 51 7.713 106.519 7.713 105.589 0 0.93 
Arg52 6.855 117.097 6.855 116.954 0 0.143 
Pro 53 ........ ---- ---- ---- ... ....... ----
Leu 54 9.73 126.366 9.692 126.252 0.038 0.114 
Pro 55 ........ ---- ---- ........ ---- .. ...... 
Gly56 ---- ---- ---- ---- ........ ----
Arg57 7.166 117.239 7.185 117.466 -0.019 -0.227 
133 
Lys 58 ---- ---- ---- ---- ........ ......... 
Asn 59 8.922 125.428 9.045 125.911 -0.123 -0.483 
Ile 60 8.809 126.565 8.731 126.366 0,078 0.199 
Ile 61 8.762 127.418 8.793 127.702 -0.031 -0.284 
Leu 62 8.159 126.025 8.174 125.939 -0.015 0.086 
Ser63 ......... ---- ---- ---- ---- ......... 
Ser64 10.154 123.039 10.16 122.954 -0.006 0.085 
Gin 65 8.602 123.21 8.627 123.153 -0.025 0.057 
Pro 66 ---- ---- ---- ......... -----
----
Gly67 7.625 109.249 7.64 109.192 -0.015 0.057 
Thr68 6.044 106.519 6.038 106.462 0.006 0.057 
Asp69 7.345 120.679 7.339 120.537 0.006 0.142 
Asp 70 8.856 126.963 8.878 126.935 -0.022 O.OZ8 
Arg71 8.885 118.461 8.878 118.376 0.007 0.085 
Val 72 7.203 108.481 7.238 108.51 -0.035 -0.029 
Thr73 7.998 117.523 7.967 117.438 0.031 0.085 
Trp 74 8.746 129.181 8.765 129.181 -0.019 0 
Val 75 9.108 116.727 9.139 116.67 -0.031 0.057 
Lys 76 8.228 116.158 8.266 116.016 -0.038 0.142 
Ser77 7.191 109.078 7.21 109.021 -0.019 0.057 
Val78 8.859 122.869 8.897 122.812 -0.038 0.057 
Asp 79 
----
........ ......... 
---- ---- ----
Glu80 7.936 120.85 7.958 120.793 -0.022 0.057 
Ala81 ........ ---- ---- ---- ......... ----
Ile82 7.926 116.187 7.964 116.215 -0.038 -0.028 
Ala83 8.096 124.006 8.14 124.091 -0.044 -0.085 
Ala84 8.036 119.57 8.074 119.485 -O.Q38 0.085 
Cys85 7.37 114.594 7.395 114.594 -0.025 0 
Gly86 7.229 131.399 7.263 131.342 -0.034 0.057 
Asp 87 8.511 122.471 8.542 122.442 -0.031 0.029 
Val88 7.235 114.936 7.263 114.879 -0.028 0.057 
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Pro 89 ---- ---- ---- ........ ........ ......... 
Glu90 7.678 117.011 7.681 116.755 -0.003 0.256 
Ile91 8.727 130.176 8.775 129.977 -0.048 0.199 
Met92 7.882 121.873 7.898 121.76 -0.016 0.113 
Val93 9.224 125.485 9.343 125.371 -0.119 0.114 
Ile94 8.498 118.717 8.771 118.348 -0.273 0.369 
Gly95 6.044 130.944 6.204 132.764 -0.16 -1.82 
Gly96 ---- ---- ---- ---- ---- ----
Gly97 7.389 108.566 7.458 108.794 -0.069 -0.228 
Arg98 9.761 123.807 9.849 123.608 -0.088 0.199 
Val99 7.48 123.068 7.42 122.442 0.06 0.626 
Tyr 100 9.532 120.452 9.434 120.31 0.098 0.142 
Glu 101 8.112 116.187 8.162 116.556 -0.05 -0.369 
Gin 102 7.266 114.338 7.216 113.997 0.05 0.341 
Phe103 8.115 113.855 8.143 113.798 -0.028 0.057 
Leu104 ---- ......... ---- ---- ---- ----
Pro 105 ---- ........ ---- ---- ---- ----
Lys 106 ........ ........ ........ ........ 
---- ----
Ala 107 7.936 122.698 7.958 122.499 -0.022 0.199 
Gin 108 9.221 118.632 9.255 118.973 -0.034 -0.341 
Lys 109 7.766 120.594 7.788 119.997 -0.022 0.597 
LeullO ---- ---- ......... ---- ---- ........ 
Tyr 111 9.334 122.499 9.372 122.527 -0.038 -0.028 
Leu112 9.632 122.556 9.654 123.38 -0.022 -0.824 
Thr113 ---- ---- ---- ---- ---- ----
His 114 ........ ........ ......... ----
---- ----
Ile 115 9.048 126.906 8.988 126.053 0.06 0.853 
Asp116 8.335 130.205 8.388 130.148 -0.053 0.057 
Ala 117 7.747 124.489 7.766 124.376 -0.019 0.113 
Glu 118 8.498 123.665 8.507 119.428 -0.009 4.237 
Val119 8.247 119.911 8.269 119.684 -0.022 0.227 
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Glu 120 8.372 124.404 8.372 124.376 0 0.028 
Gly 121 8.413 107.173 8.438 106.974 -0.025 0.199 
Asp122 8.753 116.812 8.834 116.642 -0.081 0.17 
Thr123 7.521 115.675 7.521 115.419 0 0.256 
His 124 9.513 126.792 9.592 127.418 -0.079 -0.626 
Phe125 9.262 125.314 9.29 125.086 -0.028 0.228 
Pro 126 ---- ---- ........ ........ ---- ----
Asp127 ........ ......... ---- ---- ........ ----
Tyr 128 7.471 119.684 7.533 119.599 -0.062 0.085 
Glu 129 8.812 123.75 8.822 123.466 -0.01 0.284 
Pro 130 ........ ---- ......... ---- ........ ----
Asp131 9.007 115.021 9.079 115.078 -0.072 -0.057 
Asp132 ---- ---- ---- ---- ---- ----
Trp133 7.772 119.855 7.832 119.855 -0.06 ----
Glu 134 9.551 123.153 9.604 122.982 -0.053 0.171 
Ser 135 ......... ---- ......... ---- ---- ----
Val 136 ........ 
---- ---- ----
........ 
----
Phe137 7.879 123.807 7.898 123.778 -0.019 0.029 
Ser 138 ........ ---- ........ 
---- ---- ----
Glu 139 8.683 125.911 8.454 124.802 0.229 1.109 
Phe140 ---- ........ ---- ........ ........ ........ 
His 141 8.118 123.295 8.184 122.755 -0.066 0.54 
Asp142 8.024 120.708 8.178 121.362 -0.154 -0.654 
Ala 143 ........ ........ ---- ---- .. ...... 
----
Asp144 9.051 121.418 8.995 121.134 0.056 0.284 
Ala 145 ---- ---- ---- ......... ........ ........ 
Gin 146 7.958 113.372 8.024 113.457 -0.066 -0.085 
Asn147 8.209 119.968 8.2 119.57 0.009 0.398 
Ser 148 8.881 117.21 8.815 117.097 0.066 0.113 
His 149 6.918 117.153 6.955 117.21 -0.037 -0.057 
Ser 150 8.621 114.253 8.636 113.685 -O.Q15 0.568 
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Tyr 151 7.621 114.992 7.618 114.651 0.003 0.341 
Cys 152 ---- ---- ---· ........ ......... ----
Phe153 ........ ---- ---- ---- ......... ----
Glu 154 9.749 124.347 9.698 123.978 0.051 0.369 
Ile 155 8.646 124.034 8.589 123.722 0.057 0.312 
Leu156 .......... ---- ---- ---- ---- ----
Glu 157 9.315 120.025 9.387 120.253 -0.072 -0.228 
Arg 158 8.247 127.162 8.313 127.219 -0.066 -0.057 
Arg 159 7.967 131.683 7.989 131.569 -0.022 0.114 
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Figure 3.11: Histogram of the magnitude of 1H chemical shift perturbation for each 
residue upon binding to inhibitor 1 to the DHFR:NADPH complex. 
138 
25 
20 
15 
E' 
~ 10 
CV 
Met201oop Adenoslne 
binding loop 
F-Gloop G-H loop 
~ 5 i 0 ••• .,,.. .J !I • ,, ,,..,,~.I' • ! ••• •'' ~ ·~·" "~' ~ '" ..... , ...... ~· ~ J ..... ,. " .... , ....... ~ '" 
G 
·e -s 
OJ 
.s:. 
~ -10 
11'1 
.... 
-15 
-20 
10 20 30 40 50 60 70 80 90 100 110 120 130 140 150 160 
Residue 
Figure 3.12: Histogram of the magnitude of 1sN chemical shift perturbation for 
each residue upon binding to inhibitor 1 to the DHFR:NADPH complex. 
Significant chemical shift changes were observed for residues A6, A7, M16, 
N18, W22, L28, W30, L36, V40, G43, GSl, and G95. All of these residues are in close 
proximity to the substrate (inhibitor). Analysis of the X-ray structure shows that 
one isothiourea group of the inhibitor interacts with a region of the protein that 
would form the binding pocket for the pteridine ring of the substrate and the other 
isothiourea group interacts with the Met20 loop (Figure 3.13) [126]. Residues M16 
and N18 are part of the Met20 loop active site loop and are affected by the bound 
substrate. The occluded conformation in DHFR that occurs upon substrate binding is 
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attributed to movement of residue M16 such that it protrudes into the active site, 
explaining the detected chemical shift changes. 
IFligumre 3.13: Residues (yellow) of DHFR (PDB ID: 2ANQ) [126] that are in close 
proximity to inhibitor 1 (blue) show significant chemical shift changes upon 
binding. Residue M16 in the Met20 loop is colored pink. The NADPH cofactor (red) 
does not appear to be considerably near to the residues showing chemical shift 
changes. 
NMR studies by Venkitakrishnan et al. of alanine resonances in binary and 
ternary DHFR complexes with folate, showed that A6 and A7 are responsive to 
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substrate or to both substrate and cofactor binding [119]. The 1sN resonance of A6 
is sensitive to the location of the pterin ring of the bound substrate or product [119]. 
The 1HN and lSN resonances of A7 are affected by hydrogen-bonding interactions 
with the carboxyamide group of the nicotinamide moiety of bound cofactor and to 
the bound substrate [119]. Residues W22, L28, and G51 are in close proximity to 
one of the isothiourea groups of the inhibitor, allowing for direct interactions. 
Residues W30, L36, V40, G43 and G95 are located closely to the second isothiourea 
group of the inhibitor so that direct interactions are possible. 
3.3.3 Relaxation Analysis of DHFR:NADPH 
Relaxation dispersion NMR spectroscopy was used to understand the 
dynamics of DHFR. In addition to being a powerful tool for characterizing the 
mechanisms of protein folding, this approach is often used for acquiring a detailed 
description of intermediate states in a protein's folding pathway [127]. Information 
about protein dynamics was obtained by performing Ti, Tz, {1H}-1SN NOE, and CPMG 
relaxation experiments of both the binary and ternary complexes and then 
comparing the changes in dynamics parameters. Relaxation data was obtained for 
121 residues out of 159 residues in the DHFR:NADPH complex (excluding 10 
pralines and N-terminal methionine) (Figures 3.14-3.17). The Ti values ranged 
from 428-876 ms with an associated error range of 2-15%. The average T1 value 
was determined to be 668 ms with an associated error of 6%. The Tz values ranged 
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from 46-97 ms with an associated error range from 2-19% and the average T2 value 
was determined to be 16 ms with an associated error of 6%. Residues that had 
hetNOE values above 1.0 were excluded from the hetNOE relaxation data analysis. 
HetNOE values ranged from 0.47-0.99, with an average hetNOE of 0.86. To all 
hetNOE values, 5% error was assigned. Visual examination of the data points show 
residues 6, 34, 67-69, 88, 135, and 148 have both distinctively low hetNOE values 
and Ti/T2 ratios, suggesting that these residues most likely undergo motions on the 
pico-nanosecond timescale. Conversely, high hetNOE values and low T2 times result 
in higher than average Ti/T2 ratios, which is evident for residues 9, 11, 30, 94, 97, 
121, 128, 133. These values show a possible indication for motions on the micro-
millisecond timescale. 
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3.3.4 Relaxation Analysis of DHFR:NADPH:1 
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Relaxation data was obtained for 106 residues out of a total of 159 residues 
in the DHFR:NADPH:1 complex (excluding 10 pralines and N-terminal methionine) 
(Figures 3.18-3.21). The Ti values ranged from 562-945 ms with an associated 
error range of 2-10%. The average Ti value was determined to be 803 ms with an 
associated error of 7%. The Tz values ranged from 39-102 ms with an associated 
error range from 1-7% and the average Tz value was determined to be 67 ms with 
an associated error of 2%. Residues that had hetNOE values above 1.0 were 
excluded from the hetNOE relaxation data analysis. HetNOE values ranged from 
0.48-0.99, with an average hetNOE of 0.88. To all hetNOE values, 5% error was 
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assigned. Visual examination of the data points show residues 34, 38, 58, 67-69, 80, 
88, 120, 121, 128, 129, and 131 have both distinctively low hetNOE values and T1/T2 
ratios, suggesting that these residues most likely undergo motions on the pico-
nanosecond timescale. Residues 16, 40, and 59 have high hetNOE values and 
residues 11, 23, 28, 36, 42, 128, 155, and 158 display high T1/T2 ratio, indicative of 
motions on the micro-millisecond timescale. T1 and T2 relaxation data suggests that 
the DHFR:NADPH complex shows overall motions on the micro-millisecond 
timescale, which are referred to as 'slow' timescale motions that is often observed 
due to conformational exchange or ligand binding events [128]. 
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Figure 3.18. T1 relaxation times for residues in the DHFR:NADPH:1 complex. 
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complex. 
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3.3.5 CPMG NMR Spectroscopy for Protein Dynamics 
The CPMG experiment monitors the signal intensity /(vcPMG) of spins from the 
ground state, where the signal intensity is a function of the rate of applied 
refocusing pulses that are described as VcPMG = 1/(2-r) with T being the time between 
pulses. The rate of decay of the signal can be quantified by converting /(vcPMG) into 
the effective transverse relaxation rate Eq. (11), 
Reff(VcPMG) = -ln(/(VcPMG)lo)/T (11) 
where Io is defined as the reference signal intensity. In doing so, relaxation 
dispersion (RD) profiles of Reff(VcPMG) are obtained. 15N RD profiles were generated 
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for each residue of DHFR when the protein is free (binary complex) and when 
bound to inhibitor 1 (ternary complex). Since the RD profiles depend on the 
nonlinear rates of exchange and on the differences in chemical shift, each residue 
should have a unique RD profile. Comparing the RD profiles of each protein residue 
in the binary and ternary complexes should show a difference between the shape of 
the profiles and hence provide insight into which residues are involved in protein 
folding upon binding of the inhibitor. RD profiles of the binary complex of DHFR 
showed generally straight lines for all residues whereas RD profiles of the ternary 
complex of DHFR showed slight curves for all residues (Figure 3.22 a-b ). 
Comparison of the binary and ternary data is inconclusive because a visible change 
in the profiles should be apparent for at least some protein residues only and not for 
all residues. Therefore no conclusions could be made regarding relaxation 
dispersion or protein folding of DHFR. One possible reason for this lack of 
difference may be that the exchange is not in the intermediate exchange range. 
Furthermore, acquiring CPMG data at a different frequency in addition to the 
frequency under which this data was obtained would largely improve this 
experiment. No conclusions about the protein folding of DHFR could be made from 
the CPMG relaxation dispersion data acquired. 
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3.3.6 Estimation of Global Correlation Time,'t'm 
The global correlation time ('tm) for the binary and ternary complexes was 
estimated with the program 'r2rl_tm' using the 15N Ti and Tz relaxation data. Only 
residues with T 1/T 2 ratios within one standard deviation unit of the mean were 
used for estimation of 'tm. In the binary complex for which accurate relaxation data 
could be obtained, residues A6, LB, A9, Dll, Ql 7, W30, N34, L36, V40, R57, G67-R71, 
D87, V88, I94, G97, G121, Y128, W133, S135, D142, E157, and R158 had Ti/T2 ratios 
greater or smaller than one standard deviation unit of the mean. The estimated 'tm 
for the binary complex was 9.9 ns ± 0.6 ns. For the ternary complex, residues I2, A6, 
Dll, V13, N23, L28, N34, L36, M42, K58, S64, G67-D70, D87, V88, M92, I94, Y128, 
D142, and R158 were eliminated for having Ti/T2 ratios greater or smaller than one 
standard deviation unit of the mean. The ternary complex had an estimated 'tm of 
10.8 ns ± 0.5 ns. In cases where the Ti/T2 ratio is smaller by one standard deviation 
from the mean and the hetNOE value is low, it can be concluded that fast motions 
make significant contributions to Ti and/or Tz [129]. If the Ti/T2 ratio is greater 
than one standard deviation unit from the mean, then slow motions give rise to low 
Tz values as a result of chemical exchange [129]. 
The program 'quadric_diffusion' computed the diffusion tensor for isotropic, 
axially symmetric and fully anisotropic models for the binary (DHFR:NADPH) and 
ternary (DHFR:NADPH:t) complexes (Table 3.2 and Table 3.3). Only residues with 
Ti/T2 ratios to one standard deviation unit of the mean were used to compute the 
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diffusion tensor for each model. F-statistical testing showed the largest F value for 
the axially symmetric model, indicating that the relaxation data for the binary and 
ternary complexes is best described by the axially symmetric diffusion tensor. This 
is in agreement with other relaxation studies of DHFR that also describe DHFR by 
the axially symmetric diffusion tensor [122]. Upon comparing the binary and 
ternary complexes, there is little difference between the diffusion parameters. This 
indicates that binding of inhibitor 1 to DHFR does not affect the rotational diffusion 
tensor significantly. 
Table 3.2: Isotropic, axial symmetric and anisotropic rotational diffusion tensor 
parameters for DHFR:NADPH complex. 
Tensor Diso (10-7 s-1) 2 Dzz(Dzz+ Dyy) Dxx/Dyy 0 (rad) 
Isotropic 1.638 ± 0.005 ----- ---- ----
Axial 1.640 ± 0.005 1.107 ± 0.019 ---- 0.344 ± 0.115 
Anisotropy 1.640 ± 0.005 1.108 ± 0.019 0.986 ± 0.018 0.336 ± 0.118 
Tensor <I> (rad) 'I' (rad) xz F 
Isotropic ---- ----- 233.74 ----
Axial 3.487 ± 0.333 ---- 197.18 5.56 
Anisotropy (-)2.753 ± 1.511 ± 0.834 196.82 0.08 
0.433 
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Table 3.3: Isotropic, axial symmetric and anisotropic rotational diffusion tensor 
parameters DHFR:NADPH:1 complex. 
Tensor Diso (10-7 s-1) 2 Dzz(Dzz+ Dyy) Dxx/Dyy 0 (rad) 
Isotropic 1.540 ± 0.004 ----- ---- ----
Axial 1.539 ± 0.004 0.898 ± 0.014 ---- 1.551 ± 0.112 
Anisotropy 1.538 ± 0.004 1.085 ± 0.015 0.913 ± 0.015 0.133 ± 0.360 
Tensor <I> (rad) lJI (rad) xz F 
Isotropic ---- ----- 240.99 ----
Axial 6.265 ± 0.106 ---- 191.54 6.89 
Anisotropy 1.605 ± 1.599 (-)1.551 ± 187.45 0.85 
1.118 
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3.3.7 Determining aCp ofDHFR:NADPH:Inhibitor by ITC 
The heat capacity of proteins plays a significant role in establishing the 
energetics of protein stabilization, including protein folding and molecular 
recognition [130]. The heat capacity change with binding at constant pressure, ~Cp, 
can influence the change in enthalpy (~H) and entropy (~S), which in turn will affect 
the Gibbs free energy of stabilization parameter considerably [130]. The term Cp 
directly measures the magnitude of enthalpy changes of the system at a constant 
pressure. Studies indicate that the enthalpy fluctuations are caused mainly by 
obstructed internal rotations by functional groups such as methyl groups, high 
frequency stretching and bending modes, as well as low frequency conformational 
variations. In addition, non-covalent interactions and solvent accessibility of groups 
on the protein surface affect the heat capacity of proteins [130]. 
The goal of this experiment was to determine if the crystal structure of 
DHFR:NADPH in the ground state is in the same conformation when bound to the 
ligand compared to the structure fo solution. Determining the change in heat 
capacity of binding of the complex can achieve this. In addition, the observed ~Cp is 
compared with the theoretical ~Cp. 
To determine the heat capacity of DHFR when bound to inhibitor 1 and when 
bound to the established inhibitor MTX, the enthalpy of binding at various 
temperatures is measured. Initial ITC runs that were performed with 1 injection of 
2 µL followed by 35 injections of 8 µL volumes resulted in isotherms with high C-
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values, represented by sharp isotherm curves indicating fast ligand saturation that 
did not allow for an accurate enthalpy value to be acquired. Since the enthalpy 
value is simply determined by the y-intercept, it is possible to obtain an enthapy 
value at various temperatures by performing 3 injections of 8 µL volumes at each 
desired temperature and then calculating the average (Figure 3.23-3.24). All data is 
fit to a one-site binding model and the enthalpy values are obtained. By only 
allowing for 3 injections at each temperature and not saturating the binding site, a 
curve is not generated by the data points, but rather a straight line is obtained from 
which the slope of the line can be extrapolated to the y-intercept to determine the 
associated enthalpy value. Enthalpy values were determined at a temperature 
range of 10°C to 30°C. 
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Figure 3.23: The resulting ITC chromatograms (top panels) and binding isotherm curves 
(bottom panels) of titrations of DHFR:NADPH to 1 taken over 3 injections of 8 µL. 
Titrations were performed at temperatures of (A) 10°C, (B) 15°C, (C) 20°C, and (D) 25°C. 
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Figure 3.24: The resulting ITC chromatograms (top panels) and binding isotherm 
curves (bottom panels) of titrations of DHFR:NADPH to MTX taken over 3 injections 
of 8 µL. Titrations were performed at temperatures of (A) 10°C, (8) 15°C, (C) 20°C, 
(D) 25°C, and (E) 30°C. 
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Plotting the acquired enthalpy values against temperature resulted in a 
negative straight line that is indicative of an exothermic binding reaction of 
DHFR:NADPH binding to 1 that is enthalpically favored. Similarly, DHFR:NADPH 
binding to MTX is also found to be an exothermic process that is enthalpically 
driven. Heat capacity can be determined using the equation C=~H/ ~ T where C is 
the ratio of heat energy that is transferred in the reaction that causes the resulting 
increase in temperature. Therefore, by determining the slope of the line of the 
enthalpy-temperature plot, the heat capacity of DHFR:NADPH:l is found to be 
-43 ± 10 caljmol·K (Figure 3.25) and the heat capacity of DHFR:NADPH:MTX is 
found to be -120 ± 109 caljmol·K (Figure 3.26). 
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Figure 3.25: Enthalpy-temperature plot displaying the heat capacity of 
DHFR:NADPH:l. 
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Figure 3.26: Enthalpy-temperature plot displaying the heat capacity of 
DHFR:NADPH:MTX. 
Since noncovalent interactions contribute positively to heat capacity of the 
native protein, disrupting these interactions upon unfolding will contribute 
negatively to LlCp with a large negative LlCp that is characteristic of site-specific 
binding [131]. These results suggest that at higher temperatures the DHFR:NADPH 
complex is unfolding as the noncovalent interactions are disrupted and the protein 
surface area is exposed to hydration effects. 
It has been recognized that heat capacity is influenced by the hydration of 
polar and apolar groups of the protein, where the changes in solvent accessibility is 
associated with protein folding and unfolding events [130]. Therefore, considering 
the role of the solvent is imperative for understanding protein energetics. To 
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determine the Polar Surface Area (PSA) and Apolar Surface Area (ASA) of the 
biomolecule in the free and bound forms, the computer software 'Vega' [132] was 
used to calculate the heat capacity of DHFR:NADPH when free and when bound to 
inhibitor. To do this, the crystal structure of DHFR:NADPH and the inhibitor 
involved in the binding reaction must be known. The PSA of a molecule is the 
surface sum of all the polar atoms in the biomolecule, which are usually oxygen and 
nitrogen atoms. Conversely, the ASA of the molecule is the surface sum of all the 
apolar atoms in the biomolecule [131]. This calculation is most often used to 
determine how well a molecule can permeate cells [133], however for the purpose 
of this experiment, Vega calculations are used to determine the heat capacity of the 
complex as a crystal structure in the ground state when bound to ligand. These heat 
capacity values can then be compared to heat capacity values of the complex in the 
solution state obtained by ITC. Using crystal structures from the Protein Data Bank 
(PDB), surface area values for DHFR, DHFR:NADPH, and DHFR:NADH:1 were 
generated (Table 3.4). For comparison purposes, the program Marvin Draw [134] 
was also used to obtain surface area values for the inhibitors 1 an MTX in the 
solution. 
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Table 3.4: PSA, APA, and total surface area values of DHFR and DHFR complexes 
using Vega software [132] and Marvin Draw software [134]. 
Molecule PDBID Polar Apolar Total Surface 
Surface Area Surface Area Area (A2) 
(PSA), (A2) (ASA), (A2) 
DHFR 2ANQ 4570.9 3977.0 8547.9 
DHFR 1RH3 4674.7 3927.0 8601.7 
DHFR:NADPH 1RX1 4607.2 3703.4 8310.6 
DHFR:NADPH:1 2ANQ 4419.5 3836.4 8255.9 
1 (CRYSTAL) 2ANQ 340.1 247.5 587.6 
1 (SOLUTION) n/a* 372.4 257.9 630.3 
DHFR:NADPH:MTX 1RH3 4499.2 3521.5 8020.7 
MTX (CRYSTAL) 1RH3 366.8 310.1 676.9 
MTX (SOLUTION) n/a* 392.4 284.0 676.4 
The change in heat capacity, LlCp, upon protein folding is dependent on the water 
accessible polar and nonpolar surface areas as given by Eq. (12) [131] 
LlCp = (0.32 ± 0.04 x Llnonpolar) - (0.14 ± 0.04 x Llpolar) (12) 
where the units for the constants 0.32 and 0.14 are ca1Jmol·K·A2. 
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Using the PSA and APA values generated in Table 3.4, the contribution of .1polar and 
.1nonpolar for DHFR:NADPH binding to ligand 1 can be calculated: 
.1polarcugand 1) = DHFR:NADPH + 1 ~ DHFR:NADPH:1 
= 4607.2 Az + 340.1 A2 ~ 4419.5 Az 
= -527.8 A2 
.1nonpolarcligand 1) = DHFR:NADPH + 1 ~ DHFR:NADPH:1 
= 3703.4 A2 + 247.5 A2 ~ 3836.4 A2 
= -114.S A2 
Substituting the values for .1polar and .1nonpolar into Eq. (12), the predicted change 
in heat capacity of DHFR:NADPH:1 is determined to be 37.252 ± 25.692 cal/mol·K. 
Similarly, the PSA and APA values generated in Table 3.4 is used to calculate 
the contribution of .1polar and .1nonpolar for DHFR:NADPH binding to ligand MTX: 
.1polarcligandMTXJ = DHFR:NADPH + MTX ~ DHFR:NADPH:MTX 
= 4607.2 A2 + 366.8 A2 ~ 4499.2 A2 
= -474.8 A2 
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L\nonpolar(ligand MTX) = DHFR:NADPH + MTX ~ DHFR:NADPH:MTX 
= 3703.4 A.2 + 310.1 A.2 ~ 3521.5 A.2 
= -492.0 A2 
Substituting the values for L\polar and L\nonpolar into Eq. (12), the predicted change 
in heat capacity of DHFR:NADPH:MTX is determined to be -90.968 ± 38.672 
cal/mol·K. 
The small difference seen between the observed and theoretical heat 
capacity values of DHFR binding to MTX suggests that the binding mechanism in 
solution is similar to the binding mechanism that yields the ground state 
conformation observed in the crystal structure of the complex. The binding of MTX 
to E. coli DHFR is known to be a complex process that involves multiple 
conformational states. The crystal structure of DHFR bound to MTX shows that MTX 
sits in the active site of the enzyme and the Met20 loop closes over the MTX 
molecule (Figure 3.27) [117, 126]. In this ground state conformation the Met20 loop 
is flexible since MTX does not directly interact or bind to the Met20 loop, suggesting 
that any conformational changes involves an opening and closing of the loop over 
MTX. 
Unlike MTX and other DHFR inhibitors known to date, inhibitor 1 interacts 
with the Met20 loop (Figure 3.28). This interaction is particularly interesting 
because the Met20 loop has an important role in the structural changes that occur in 
163 
the binding mechanism [116]. The observed heat capacity of DHFR:NADPH binding 
to 1 is significantly different from the theoretical heat capacity, indicating that the 
mode of binding may be considerably different in solution compared to that 
achieved for the conformation of the complex in the crystal structure. The structure 
of the DHFR:NADPH complex represented in the X-ray structure (lRXl) may not be 
the structure that binds inhibitor 1. Rather, inhibitor 1 may be bound by a different 
structure that did not crystallize or is only transiently populated. Since the inhibitor 
makes contacts with the Met20 loop, this loop is held in place and becomes less 
flexible and more rigid in structure. This stability contributes positively to heat 
capacity when the complex is in the crystal structure. However, in solution, 
disruption of these interactions and changes to the how the contacts are made or 
how many contacts are made will affect the magnitude of enthalpy changes of the 
system and contribute negatively to the heat capacity of the complex formation such 
that the heat capacity has a more negative value. 
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Figure 3.27: Crystal structure illustrating the Met20 loop (pink) of E. coli DHFR 
closing over inhibitor MTX (orange) (PDB ID: 1RH3) [117]. 
Figure 3.28: Crystal structure illustrating the Met20 loop (pink) of E. coli DHFR 
interacting with inhibitor 1 (blue) (PDB ID: 2ANQ) [126]. 
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3.4 CONCLUSIONS 
DHFR is dynamic in nature and conformational changes are necessary for 
substrate binding and product release to be executed efficiently. In order to 
determine how inhibitor binding affects the catalytically important motions of E. coli 
DHFR, 1sN relaxation parameters were measured upon binding of inhibitor 1 by 
employing well established NMR relaxation methods that use Ti, Tz, 1H-15N NOE, 
and CPMG pulse sequences. In the presence of inhibitor 1, the catalytic domain of 
DHFR binds 1 in the substrate-binding pocket and an occluded conformation is 
assumed as residues in and around the Met20 loop exhibit significant motions. In 
both the DHFR:NADPH and DHFR:NADPH:t complexes mobility is observed in the 
Met20, F-G and G-H loops as well as the adenosine binding loop (residues 67-69) as 
reflected by low 1H-15N-NOE values, non-average Ti/T2 values and significant Tm 
values. These results are in good agreement with the general dynamic features of 
DHFR presented in studies from the Wright laboratory that analysed the dynamics 
of DHFR:folate, DHFR:DHNADPH:folate and DHFR:NADP+:folate complexes [121, 
122]. The Wright laboratory reported that significant motions were found to occur 
in the occluded complexes (DHFR:folate and DHFR:DHNADPH:folate ), whereas in 
the closed complex (DHFR:NADP+:folate) motion in the Met20 and F-G loops is 
reduced. The relaxation data presented here in this dissertation show that the 
catalytically important Met20 and F-G loops in both DHFR:NADPH and 
DHFR:NADPH:t complexes most closely resembles that of the closed DHFR complex. 
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These findings are consistent with the analysis of the X-ray structure [126]. DHFR 
exhibits motions on the microsecond-millisecond timescale that is indicative to 
motions that can be attributed to either conformational exchange within the protein 
and biochemical events such as ligand binding. Future studies include determining 
if this effect on DHFR dynamics is seen with other DHFR inhibitors. It is possible 
that compounds that favor the formation of the closed conformation could lead to 
more efficient DHFR inhibitors. 
The estimated 'tm for both binary and ternary complexes was in the 
nanosecond timescale. Although the relaxation data could not be fit by the FAST-
M odelFree automated model-fitting program, information about the diffusion tensor 
dynamics of the binary and ternary complexes were determined. Relaxation data 
for the binary and ternary complexes is best described by the axially symmetric 
diffusion tensor, which is consistent with previous relaxation studies of DHFR [121, 
122]. Upon comparing the binary and ternary complexes, there is little difference 
between the diffusion parameters, indicating that binding of inhibitor 1 to DHFR 
does not significantly affect the rotational diffusion tensor. An observed increase in 
'tm is indicative of a restriction of rotational freedom of the entire molecule upon 
formation of the ternary complex, which is consistent with a large molecular weight 
complex. 
Heat capacity changes of DHFR:NADPH upon binding to the inhibitor MTX 
provided an understanding of the energetic contributions to the stability of the 
protein-inhibitor complexes of DHFR that is currently not known. Inhibitor binding 
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with DHFR is shown to be an exothermic process as protein folding and structural 
stability is increased and protein flexibility is reduced. Since the MTX inhibitor does 
not interact with the Met20 loop, the loop is flexible and the binding mechanism in 
solution is similar to that observed in the crystal state where the presence of the 
inhibitor demonstrates positive binding cooperativity and the affinity of DHFR for 
NADPH is enhanced upon inhibitor binding [126, 135]. Conversely, inhibitor 1 does 
interact with the Met20 loop. Inhibitor 1 in the presence of the cofactor also leads 
to positive binding cooperativity and the affinity of DHFR:NADPH for 1 is 
comparable to inhibitors of DHFR such as MTX whose Kd ranges from 10-8M to less 
than 10-11M depending on the presence of cofactors and the source of DHFR [135-
138]. However, differences in ~Cp of DHFR binding to inhibitor 1 compared to that 
of MTX indicate that the mode of binding to 1 is different from what is observed in 
the crystal structure of the complex. It is likely that the structure that binds to 1 did 
not crystallize or that the structure is transiently populated. 
168 
CHAPTER4 
THE DEVELOPMENT OF AN AFFINITY ELECTROPHORESIS METHOD FOR 
SCREENING RNA-SMALL MOLECULE INTERACTIONS 
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PREFACE 
This chapter presents work from two separate papers - one published and one 
accepted at the time of writing this dissertation. The published paper illustrates that 
the affinity electrophoresis method [139] described in this chapter works successfully. 
The work outlined in the accepted paper demonstrates how the affinity electrophoresis 
method previously described can be made quantifiable by cross-linking the ligand to 
the gel matrix. 
4.0 AMINOGLYCOSIDE ANTIBIOTICS 
The ability of RNA to interact with small molecules is the basis for a wide 
assortment of biochemical functions. In nature, RNA-small molecule interactions in 
riboswitches regulate gene expression [140, 141] while in biotechnology 
applications, RNA aptamers can be selected as biosensors for small molecules [142]. 
In addition, the interactions between RNA and small molecules govern the action of 
a number medicinally important molecules such as the aminoglycoside class of 
antibiotics (Figure 4.1) [143, 144]. The chemical and structural diversity of 
antibiotics makes these molecules particularly interesting for understanding the 
binding specificity of RNA for its target ligands [24, 145-147]. Aside from its 
interactions with small molecules, it is clear that RNA has many other important 
functions in cellular processes [35, 39, 148]. Controlling the biological function of 
RNA through the binding of a small molecule would be a powerful biochemical tool. 
For this reason, developing a method of quickly and easily identifying compounds 
that bind to RNA of a defined size or shape is very beneficial. 
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Paramomycin Neomcyin B 
Gentamicin 
Figure 4.1: Chemical structures of the aminoglycoside antibiotics used in this 
affinity electrophoresis study. 
There are many biophysical methods available to study RNA-small molecule 
interactions including isothermal titration calorimetry (ITC), surface plasmon 
resonance (SPR) and fluorescence anisotropy. However, many of these techniques 
require specialized and expensive equipment. While the interaction of RNA with 
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proteins is often readily investigated using a simple electrophoretic mobility shift 
assay (EMSA) or gel shift assay [149, 150], this technique is limited when applied to 
RNA-small molecule systems because of the negligible difference in mobility 
between free and bound RNA. An alternate gel-based method for determining 
binding affinity is affinity electrophoresis. In this method, the gel, usually 
acrylamide, is polymerized in the presence of a ligand so as to embed the ligand into 
the gel matrix. A biomolecule is then run on the gel, and binding is gauged by the 
difference in mobility between gels run with and without the ligand or between a 
lane containing a nonbinding standard and the biomolecule being studied. This 
technique has been particularly widely used in the area of protein-carbohydrate 
interactions to identify which carbohydrates are bound by a particular protein and 
also to quantify binding [151-154]. For RNA-peptide interactions, a modified 
affinity electrophoresis method, polyacrylamide gel coelectrophoresis (PACE), was 
developed [155]. In the PACE method, a gel containing bands of different 
concentrations of peptide is prepared, and then the RNA is run through these 
different bands. Binding is assayed by the decrease in mobility of the RNA in bands 
of higher concentration of peptide. Although several examples have been published 
that detects the binding of molecules using affinity electrophoresis, in each case this 
technique has been limited to interactions involving proteins or peptides with 
another molecule [91, 153-156]. 
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4.1 RESEARCH GOALS 
This project aimed to show that affinity electrophoresis could be used to 
detect RNA-small molecule interactions [139]. In this method, the acrylamide gel is 
polymerized in the absence and presence of ligand such that the ligand is embedded 
into the gel matrix during polymerization. The RNA molecule is then run through 
the gel and binding is gauged by the difference in mobility of the bands between the 
gels polymerized with and without ligand. To demonstrate the validity of this 
method, the ribosomal A-site aminoglycoside interaction is used as the model 
system (Figure 4.2). In addition, this method is used to determine the range of 
aminogylcoside molecules that can be bound by the CC mismatch-containing RNA 
molecule from the thymidylate synthase mRNA construct (TSMC) (Figure 4.2). To 
achieve these objectives, the A-site RNA and TSMC RNA was used to guage the 
affinity to aminoglycoside ligands paromomycin, neomycin B, and gentamicin. As a 
control, mobility is also compared with a non-binding internal standard. While this 
method can identify interactions between small molecules and RNA, the binding is 
not quantifiable as the small molecule ligand can move in the gel during 
electrophoresis. For the ligand to be stationary during electrophoresis it must either 
be uncharged or too large to move through the gel. Aminoglycosides are neither. 
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Figure 4.2: Sequence and secondary structures of the two RNA molecules used in 
this study. TSMC is the thymidylate synthase mRNA construct containing the CC 
mismatch and A-site is the£. coli ribosomal A-site. 
To make this method quantifiable, the affinity electrophoresis method 
developed was modified to make the technique quantifiable for RNA-small molecule 
interactions. To achieve this, a chemical modification of the aminoglycoside was 
made by attaching an acrylamide monomer onto the structure. This modified 
aminoglycoside was then added to the acrylamide mixture during polymerization 
with the results so that the ligand becomes covalently attached to the gel, and 
cannot move during electrophoresis (Figure 4.3). By measuring the relative 
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migration values (Rf) and plotting 1/Rr versus ligand concentration, a straight line is 
obtained from which an apparent Kd can be determined. 
-CH2-CH-CH2-CH-CH2-CH-
I I I 
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Figure 4.3: Diagram of our scheme for generating a polyacrylamide gel cross-linked 
with an aminoglycoside. X in the diagram is an aminoglycoside molecule. 
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4.2 MATERIALS AND METHODS 
4.2.1 RNA Preparation 
The TSMC RNA was prepared by in vitro transcription [157] in a manner 
previously described [139, 158]. The A-site RNA was purchased from the University 
of Calgary DNA Services and the same sequence used previously for nuclear 
magnetic resonance (NMR) structural studies by the Puglisi group [159] and by us, 
the Johnson group, for studying the binding of new non-aminoglycoside A-site 
binding compounds [160]. 
4.2 .2 Synthesis of Cross-Linked Aminoglycoside-Acrylamide 
In a flame-dried vial containing a stirrer, aminoglycoside sulfate salt (0.5 
mmol, 1.0 equiv.) was added before it was sealed with a septum. The vial was 
purged under high vacuum and backfilled with argon (g) three times before a ddH20 
solution (totaling 1 mL) containing Na2C03 ( 46 mg, 0.55 mmol, 1.1 equiv.) was 
added via syringe. The resultant yellow suspension was sonicated for 5 min until the 
mixture was solubilised completely. To the clear, yellow solution was added acryloyl 
chloride (SO µL, 0.55 mmol, 1.1 equiv.) in one portion via microlitre syringe. The 
resultant solution was left to stir at room temperature for 24 h and was carried 
forward for polymerization reactions without further purification. 
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4.2.3 Affinity Gel Electrophoresis Preparation 
Method 1 - Detection of RNA-Small Molecule Interactions 
Polyacrylamide non-denaturing electrophoresis gels of the A-site RNA and 
TSMC RNA were run in the absence and presence of varying amounts of the 
aminoglycosides paromomycin, gentamicin, and neomycin B (Sigma). Gels were 
prepared using the Bio-Rad Mini-PROTEAN 3 apparatus using a 10 cm x 7.5 cm x 
0.75 mm gel. All gels were run in a 0.5x Tris/Borate/EDT A (TBE) buffer (1 x TBE: 9 
mM TRIS, 9 mM boric acid, 0.3 mM EDTA) at room temperature for 30 minutes at 
300 V using the constant current setting. Bromophenol blue/xylene cyanol 
(blue/green dye) was run as an internal standard. RNA was detected using Stains-
All (Sigma). The concentration of RNA used was 0.13 mM for the TSMC RNA and 
0.14 mM for the A-site RNA. 
Method 2 - Quantification of RNA-Small Molecule Interactions 
For both the cross-linked and embedded gel preparation, 20% 
polyacrylamide (19:1 acrylamide:bisacrylamide) non-denaturing electrophoresis 
gels of the TSMC RNA were run along with a control gel containing varying amounts 
of the appropriate aminoglycosides paromomycin and neomycin B (Sigma-Aldrich). 
Gels were prepared using the Bio-Rad Mini-PROTEAN 3 apparatus using a 10 cm x 
7.5 cm x 0. 75 mm gel. All gels were run in a 0.5x Tris/Borate/EDTA (TBE) buffer (1 
x TBE: 9 mM TRIS, 9 mM boric acid, 0.3 mM EDTA) at room temperature for 30 
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minutes at 300 V using the constant current setting. Bromophenol blue/xylene 
cyanol (blue/green dye) was run as an internal standard. RNA was detected using 
Stains-All (Sigma-Aldrich). In each lane, 1 µL of an RNA solution was loaded. The 
RNA solution was composed of a 1:1 mixture of 0.13 mM TSMC RNA:50% glycerol 
(v/v). 
4.2.4 Affinity Gel Electrophoresis Analysis 
The affinity electrophoresis gels were analysed according to the method of 
Takeo [91] in order to quantify the average apparent binding affinity. This method is 
summarized here. For the equilibrium between a macromolecule (M) and a ligand 
(L): 
M + L ~ML 
The apparent dissociation constant is given by Eq. (14): 
K _ [M][L] 
d - [ML] 
(13) 
(14) 
If the distance migrated by the macromolecule in the absence of ligand is given by Ra 
and the distance migrated in the presence of a particular concentration of ligand is r, 
then: 
R0 = [M], = [ML]+ [M] = [ML]+ l 
r [M] [M] [M] (15) 
where [M]t is the total concentration of the macromolecule. If Eq. (14) is rearranged 
and substituted into Eq. (15), then: 
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In our graphs we define the relative migration Rr as: 
Therefore Eq. (16) becomes: 
r R=-
1 R 
0 
(16) 
A plot of -1-versus [L] will give a straight line with a slope of - 1- under conditions 
Rf Kd 
where the total concentration of the ligand (L) is much greater than the total 
concentration of macromolecule. 
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4.3 RESULTS 
4.3.1 Detection of RNA-Small Molecule Interactions 
Affinity electrophoresis gels were used to show binding between 
aminoglycosides and the A-site RNA and the TSMC RNA (Figure 4.4). Both the A-site 
RNA and TSMC RNA samples were run in a polyacrylamide gel prepared in the 
absence of aminoglycosides and gels polymerized in the presence of 0.5% (w /v) of 
the aminoglycosides paromomycin, gentamicin, and neomycin B. Clearly, in the gels 
containing aminoglycosides, the mobility of the RNA is greatly reduced compared 
with the gel run in the absence of ligand. This decreased migration indicated that 
binding is occurring in the gel between the RNA and the aminoglycoside, and this 
binding reduces the mobility of the RNA in the gel. 
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No ligand Paromomycin Gentamicin Neomycin B 
TSMC A-site TSMC A-site TSMC A-site TSMC A-site 
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Figure 4.4: Affinity electrophoresis demonstrating the interaction of the TSMC RNA 
and A-site RNA molecules with aminoglycoside ligands. Shown are nondenaturing 
20% polyacrylamide gels containing no ligand and 0.5% (w /v) paromomycin, 
gentamicin, and neomycin B. Four different volumes (1, 2, 4, and 6 µL) of each RNA 
(0.13-0.14 mM) are loaded. All four gels were run in parallel at room temperature 
for the same total time. 
As a control, gels were also run where 0.2% (w /v) maltotriose and sucrose 
were present in the gel and compared these gels with ones where no ligand and 
0.2% (w /v) paromomycin were added (Figure 4.5). Maltotriose and sucrose were 
chosen as controls because they, like paromomycin, are oligosaccharides. The TSMC 
RNA in the gels with maltotriose and sucrose ran a similar distance as in the gel with 
no ligand, whereas the mobility of the RNA was greatly reduced in the gel with 
paromomycin (Figure 4.5). 
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No Ligand 
1 2 3 4 5 
0.2% Maltotriose 
1 2 3 4 5 
0.2% Sucrose 0.2 % Paromomycin 
12 3 4 5 1234 5 
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Figure 4.5: Native gel electrophoresis of TSMC RNA in the absence of ligand added 
to the gel and in the presence of 0.2% maltotriose, 0.2% sucrose, and 0.2% 
paromomycin. Shown in lane 1 is the bromophenol blue dye marker, and lanes 2, 3, 
4, and 5contain1, 2, 4, and 6 µL of 0.13 mM TSMC RNA, respectively. The gel is 20% 
acrylamide. Relative to the bromophenol blue dye, the gels with sucrose and 
maltotriose show no retardation of the RNA. A decrease in mobility is seen in the 
gel with paromomycin. 
When performing affinity electrophoresis, a number of experimental factors 
needed to be optimized to obtain the best results. As shown in Figure 4.4, the 
amount of material loaded into the gel is one of the factors that needed to be 
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optimized. Enough RNA needed to be loaded to ensure detection of the complex in 
the gel, whereas too much RNA leads to increased band size caused by streaking or 
smearing of the band and decrease in migration of the RNA. For the two RNA 
samples analyzed here, the best results were obtained by loading 0.13 nmol (1 µL of 
a 0.13 mM RNA solution) of RNA. An additional factor we tested was the acrylamide 
concentration in the gel. Affinity electrophoresis in gels were performed with both 
12% and 20% acrylamide (data not shown). In all cases, a clearer distinction 
between bound and free RNA was obtained with 20% gels, although the time need 
to run the gel increased at higher acrylamide concentrations. 
Both the A-site RNA and TSMC RNA display different affinities for the 
different aminoglycoside ligands. This different affinity is reflected in a different 
mobility of these RNA molecules in the gels containing different aminoglycosides. 
Figure 4.6 shows gels of the A-site RNA and TSM C RNA molecules run in the 
presence of 0.2% (w /v) paromomycin, neomycin B, and gentamicin. The affinity of 
these two RNA molecules for these ligands has been studied in solution with both 
the A-site RNA and TSMC RNA binding neomycin B with higher affinity than 
paromomycin [144], [161], [162, 163]. This known difference in solution binding 
affinity is reflected in the affinity electrophoresis technique. In the gel containing 
neomycin, the RNA migrates a significantly shorter distance than in the gel 
containing paromomycin (Figure 4.6). For the A-site RNA, there is a previous report 
that gentamicin has a slightly lower ICso value than paromomycin [164]. This likely 
reflects a higher affinity for gentamicin compared with paromomycin. Again these 
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affinity electrophoresis results are consistent with the known solution affinity, with 
both RNA molecules tested migrating slower in the presence of gentamicin than 
with paromomycin in the gel. Although the affinity of the TSMC RNA for gentamicin 
has not been reported previously, from the slower migration of TSM C in the 
presence of gentamicin compared with paromomycin, it is predicted that the TSMC 
binds paromomycin weaker than gentamicin and that TSMC binds neomycin B the 
tightest among these three ligands. 
Paromomycin Gentamicin Neomycin B 
TSMC A-site TSMC A-site TSMC A-site 
Figure 4.6: Affinity electrophoresis demonstrating the difference in interaction of 
the TSMC RNA and A-site RNA molecules with aminoglycoside ligands. Shown are 
nondenaturing 20% polyacrylamide gels containing 0.2% (w /v) paromomycin, 
gentamicin, and neomycin B. All gels were run in parallel for the same time at room 
temperature. To best differentiate between the different ligand/RNA combinations, 
the RNA in the gel containing no ligand was allowed to run out of the gel; therefore, 
it is not shown. 
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The affinity electrophoresis screen presented here displays dose-dependent 
binding between the ligand and RNA. The ligand concentration embedded in the gel 
was varied and the relative migration of the same amount of TSM C RNA in the 
different gels was measured. Figure 4. 7 shows that in the presence of a lower 
concentration of ligand, the RNA molecules migrate faster than at higher ligand 
concentrations. 
No Ligand 0.01 % 0.02 % 0.05 % 0.1 % 0.2 % 
12 3 12 3 12 3 12 3 12 3 12 3 
Figure 4.7: Affinity electrophoresis demonstrating the difference in mobility of the 
TSMC RNA with different concentrations of ligand in the gel. Shown are 20% 
polyacrylamide gels containing 0, 0.01, 0.02, 0.05, 0.1 and 0.2% (w /v) 
paromomycin. Shown in lane 1 is the bromophenol blue dye marker, and lanes 2 
and 3 contain 1 and 2 µL of 0.13 mM TSMC RNA respectively. All gels were run at 
room temperature. 
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As an internal standard the migration of the RNA compared with the 
bromophenol blue dye was measured. As seen in Figure 4.8 (a), if the relative 
migration is plotted against paromomycin concentration, the distance the TSM C 
moves plateaus at the highest concentrations of paromomycin. 
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Figure 4.8: Affinity plots for the interaction of the CC mismatch-containing RNA 
hairpin from the TSMC with the aminoglycoside paromomycin. (A) The relative 
migration (Rr) of the TSM C RNA is plotted against the amount of paromomycin 
present in the gel. (B) The reciprocal of the relative migration (1/Rr) of the TSMC 
RNA is plotted against the amount of paromomycin. 
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4.3.2 Quantification of RNA-Small Molecule Interactions 
In order to prevent the aminoglycoside ligand from moving in the gel during 
electrophoresis, paromomycin and neomycin B aminoglycosides were reacted with 
acryloyl chloride to form an acrylamide-aminoglycoside (Figure 4.9). Formation of 
the acrylamide-aminoglycoside is straightforward. With the conditions used, there 
is on average one acrylamide added per aminoglycoside molecule. However, there is 
no control over the location of the acrylamide monomer and the acryloyl chloride 
could react with any of the amine or alcohol groups on the aminoglycoside. A 
mixture of acrylamide-aminoglycoside products that differ by the location of the 
acrylamide monomer are produced. 
187 
Paramomycin, R = OH 
Neomcyin B, R = NH2 
Figure 4.9: Reaction scheme for cross-linked acrylamide-paromomycin and 
acrylamide-neomycin B, when R=OH and R=NH3+ respectively. One product is 
shown from a potential range of cross-linked acrylamide products. 
Confirmation of acrylamide-aminoglycoside synthesis was made by infrared 
(IR) and high-resolution mass spectrometry (HRMS). 1H and 13C NMR was also 
performed on the products in D20, however, these results were inconclusive due to 
extensive peak overlap. IR spectra indicate a loss of the 0-H stretch and N-H stretch 
for both cross-linked acrylamide-aminoglycosides compared to the free 
aminoglycosides. This loss of the 0-H stretch and N-H stretch suggests that the 
acryloyl chloride is reacting with both the alcohol and amine groups on the 
aminoglycoside. HRMS provided exact molecular weights of the expected 
acrylamide-aminoglycoside products. For the cross-linked paromomycin, the 
determined value of 638.3015 m/z matched the theoretical HRMS value of 638.3010 
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m/z. Similarly, the cross-linked neomycin had a determined value of 637.3170 m/z 
that exactly matched the theoretical value of 637.3170 m/z. Since it was only 
necessary that the acrylamide monomer be attached to the aminoglycoside, 
purification and isolation of the cross-linked acrylamide-aminoglycoside was not 
required. As a result, yields were not determined. 
Cross-linking of the acrylamide-aminoglycoside was performed by adding 
the desired amount of the acrylamide-aminoglycoside to the acrylamide mixture 
prior to adding tetramethylethylenediamine (TEMED) and ammonium persulfate 
(APS) polymerizing agents. Affinity gel electrophoresis was performed using either 
cross-linked ligands of acrylamide paromomycin or acrylamide neomycin B. 
Addition of the acrylamide-aminoglycoside had no observable effect on gel 
polymerization. As a control, gels were also prepared with either embedded 
paromomycin or embedded neomycin B [139]. 
RNA binding to the cross-linked acrylamide-aminoglycoside was analysed 
using the interaction of the TSMC RNA with aminoglycoside molecules as a model 
system [139, 144, 158]. The interaction of the TSMC RNA with paromomycin was 
previously characterized by ITC methods. In all cases where an aminoglycoside is 
present, the mobility of the RNA is greatly reduced compared with the gel run in the 
absence of ligand (Figure 4.10 and Figure 4.11). Moreover, the gels containing cross-
linked paromomycin show that RNA mobility is significantly reduced compared 
with the embedded paromomycin (Figure 4.10 and Figure 4.12). Similarly, the gels 
containing cross-linked neomycin B show decreased RNA mobility compared with 
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the embedded neomycin B (Figure 4.11 and Figure 4.12). This decreased migration 
indicates that binding is occurring in the gel between the RNA and the 
aminoglycoside, and that cross-linking the aminoglycoside to the acrylamide results 
in a significant decrease of RNA mobility compared with the embedded ligand. 
0.01% 0.02% 0.05% 0.1% 0.2% 
No Ligand Embedded Crosslinked Ernbeded Crosslinked Embedded Crosslinked Embedded Crosslinked Embedded Crosslinked 
Ligand Ligand Ligand Ligand Ligand ligand Ligand Ligand Ligand Ligand 
2 1 2 1 1 2 1 1 2 1 1 2 1 2 1 2 I 2 
·c :.i.. 
Figure 4.10: Affinity electrophoresis demonstrating the difference in mobility of the 
TSMC RNA between embedded and cross-linked paromomycin. Shown are separate 
gels containing different concentrations of paromomycin when co-polymerized 
within the gel matrix (embedded) versus when the ligand is cross-linked to the gel 
matrix. Compared to the gels with embedded aminoglycoside, decreased mobility of 
the TSMC RNA is observed when paromomycin is cross-linked to the gel matrix. 
Shown are 20% polyacrylamide gels containing 0, 0.01, 0.02, 0.05, 0.1, 0.2% (w /v) 
paromomycin (embedded and cross-linked). In each gel, lane 1 is the bromophenol 
blue internal standard and lane 2 contains the TSMC RNA. 
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0.01% 0.02% 0.05% 0.1% 0.2% 
No Ligand Embedded Crosslinked Embedded Crosslinked Embedded Crosslinked Embedded Crosslinked Embedded Crosslinked 
Ligand Ligand Ligand Ligand Ligand Ligand Ligand Ligand Ligand Ligand 
12 12 12 12 12 12 12 12 1 2 1 
Figure 4.11: Affinity electrophoresis demonstrating the difference in mobility of the 
TSMC RNA between embedded and cross-linked neomycin B. Shown are separate 
gels containing different concentrations of neomycin B when co-polymerized within 
the gel matrix (embedded) versus when the ligand is cross-linked to the gel matrix. 
Compared to the gels with embedded aminoglycoside, decreased mobility of the 
TSMC RNA is observed when neomycin B is cross-linked to the gel matrix. Shown 
are 20% polyacrylamide gels containing 0, 0.01, 0.02, 0.05, 0.1, 0.2% (w /v) 
neomycin B (embedded and cross-linked). In each gel, lane 1 is the bromophenol 
blue internal standard and lane 2 contains the TSMC RNA. 
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Figure 4.12: Plots comparing the relative migration (Rr) between TSMC RNA 
interacting with the cross-linked paromomycin and cross-linked neomycin B (red 
squares) and TSMC RNA interacting with the embedded paromomycin and 
embedded neomycin B (black diamonds). 
The TSMC RNA interacted with the cross-linked aminoglycosides to produce 
quantifiable data. This interaction was analyzed by measuring the relative migration 
(Rr) of the TSMC RNA against the bromophenol blue internal standard and plotting 
the Rr value against the concentration of cross-linked and non-cross-linked 
paromomycin and to the concentration of cross-linked and non-cross-linked 
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neomycin 8 (Figure 4.12). Plotting of the reciprocal relative migration (1/Rf) against 
the concentration of cross-linked paromomycin and against the concentration of 
cross-linked neomycin B (Figure 4.13 (A) and (8)) generated straight lines from 
which the corresponding apparent dissociation constants were determined from the 
inverse of the slope of the lines [92]. From the data in Figure 4.13 an apparent Kct 
value of 156 ± 7 µM was calculated for TSMC RNA binding cross-linked 
paromomycin and an apparent Kct value of 450 ± 31 µM was calculated for TSMC 
RNA binding cross-linked neomycin 8. In comparison, the use of embedded ligands 
is not quantifiable as a straight line does not result when plotting 1/Rf versus 
aminoglycoside concentration (Figure 4.13 C and D). 
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Figure 4.13: Plots showing the quantitative binding between cross-linked 
aminoglycosides and the TSMC RNA. Binding affinity is determined from the slope of 
the straight line given by the plot of the reciprocal of the relative migration (1/Rr) of 
TSMC RNA versus ligand concentration of (A) cross-linked paromomycin and (B) 
cross-linked neomycin B. In comparison, plots of the (C) embedded paromomycin 
and (D) embedded neomycin B do not result in a straight line. 
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4.4 DISCUSSION 
4.4.1 Detection of RNA-Small Molecule Interactions 
This study has shown that affinity electrophoresis can be used to screen for 
RNA-small molecule interactions. This assay is quick and easy to perform, and it can 
be carried out with readily available equipment that can be found in nearly any 
biochemistry laboratory. This project used affinity electrophoresis to look at RNA-
aminoglycoside interactions, but it should be possible to perform affinity 
electrophoresis with any potential RNA binding ligand provided that it does not 
interfere with the gel polymerization. In addition, this screen could be run to assay 
different RNA sequences or structures to test their binding ability to different 
aminoglycsides or other RNA-binding ligands. 
This method was verified using two known aminoglycoside binding RNA 
systems, the RNA run in the ligand-containing gel ran slower than in the absence of 
ligand, demonstrating that binding takes place within the gel matrix. This mobility 
decrease is dose dependent in that higher concentrations of ligand porogressively 
reduced the RNA mobility. The mobility also varied between different 
aminoglycoside ligands, and this mobility decrease tracked the known solution 
affinity between the different aminoglycosides. 
Affinity electrophoresis can be applied in both a qualitative and quantitative 
fashion [156]. To be quantitative and obtain a dissociation constant for the 
biomolecule-ligand interaction from affinity electrophoresis, the ligand must not 
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migrate during electrophoresis. This is typically accomplished by the use of an 
uncharged ligand or a ligand with a large enough molecular size that it cannot 
migrate trough the gel during electrophoresis. Unfortunately, in the case of the 
RNA-aminoglycoside combination used here, these two requirements are not met. 
The aminoglycoside molecules are charged and are small enough to migrate through 
the gel during the course of the experiment. The putative migration of the ligand 
during electrophoresis does not prevent the observation of the occurrence of ligand 
binding, but it does preclude the determination of an absolute dissociation constant 
(Kd). In Figure 4.7, the TSMC RNA shows a dose response to an increase in the 
amount of paromomycin in the gel. This interaction was quantified by measuring 
the relative migration (Rr) of the TSMC RNA against the bromophenol blue dye and 
plotting the relative migration against the paromomycin concentration (Figure 
4.12). For a quantitative analysis, the plot of the reciprocal of the Rr to the 
paromomycin concentration should result in a straight line. As seen in Figure 4.13 
(C), this plot is not a straight line, confirming the non-quantitative nature of this 
analysis. Even though Kd values cannot be determined, it is still possible to 
determine relative affinity constants between two ligands of the same or very 
similar charge and size. One method to make the affinity electrophoresis of RNA-
aminoglycoside interactions quantifiable would be to covalently cross-link the 
aminoglycoside to the polyacrylamide gel. This would prevent migration of the 
ligand during the course of the experiment, allowing the relative migration 
distances to be used to determine dissociation constants. 
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4.4.2 Quantification of RNA-Small Molecule Interactions 
This research used affinity electrophoresis coupled with cross-linking of the 
ligand to the gel matrix to quantitatively study RNA-aminoglycoside interactions. 
Previously, using only embedded ligands, it was shown that binding occurred in a 
dose-dependent manner. However, when plotting 1/Rr values versus ligand 
concentration a straight line was not obtained with the embedded ligands [139] 
(Figure 4.13 (C) and (D)). This prevented binding being quantified. This non-
linearity was attributed as being due to the ligand moving in the gel during 
electrophoresis. Here, this limitation was resolved by cross-linking the 
aminoglycoside directly to the gel by reacting the aminoglycoside with acryloyl 
chloride. During gel polymerization, the ligand becomes covalently attached to the 
gel. Using this method, the TSMC RNA that interacts with the aminoglycoside binds 
significantly tighter to the cross-linked ligand than to the embedded ligand and 
binding approaches saturation at the higher ligand concentrations examined (Figure 
4.12). To the best of our knowledge this is the first example of cross-linking of a 
small-molecule ligand to the polyacrylamide gel to study RNA-small molecule 
interactions. 
Using the cross-linked aminoglycosides an apparent Kd value was 
determined for the RNA-ligand interaction (Figure 4.13). The term apparent Kd was 
defined as when the acryloyl chloride reacted with the aminoglycoside to get a 
mixture of products, with the acryloyl group potentially reacting with each alcohol 
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and amino group. Rings I and II on the aminoglycoside (Figure 4.1) are the rings that 
most closely interact with the RNA [165]. When the acryloyl group reacts with 
alcohol or amine groups on ring I or II, binding will be obstructed and the apparent 
Ka value increased compared to when the acryloyl reacts at rings III or IV. This 
mixture of products, with some products binding weaker than others, results in the 
measured apparent Ka being weaker (156 ± 7 µM) than what was previously 
measured in solution (0.6 µM; [144]). However, this does not take away from the 
research's main conclusion that using the cross-linked aminoglycoside results in 
quantifiable data as shown by the linear plots in Figure 4.13. 
The apparent Ka values showed tighter binding for the cross-linked 
paromomycin than for the cross-linked neomycin B (Figure 4.13). Though binding of 
neomycin B to the TSMC RNA construct used here has not been previously 
demonstrated, the binding of neomycin B to a similar CC mismatch was shown to be 
tighter than to paromomycin. This apparent discrepancy is likely due to the fact that 
neomycin B has more amino groups in ring I than has paromomycin (Figure 4.1 ). 
Since the pKa of the amino is lower (approximate pKa = 9-10) than that of the 
hydroxyl group (pKa = 16-17), the one equivalent of sodium bicarbonate will 
preferentially deprotonate the amino to form a reactive amine with an available 
lone pair that immediately reacts with acryloyl chloride. Since neomycin B contains 
more amine groups at ring I, reaction with acryloyl chloride reduces the ligand 
binding ability of neomycin B for the TSMC RNA to a greater extent than reaction of 
paromomycin. 
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This method was primarily used to quantify RNA-aminoglycoside 
interactions, however it should be possible to apply this method to any ligand that 
binds RNA as long as the cross-linked ligand does not interfere with gel 
polymerization. In addition, this cross-linked ligand affinity electrophoresis method 
is particularly useful for comparing interactions between different RNA molecules 
to the same aminoglycosides by running a constant concentration of each RNA on 
the same gel. 
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4.5 CONCLUSIONS 
We have presented an affinity electrophoresis-based method for screening 
RNA-small molecule interactions. This method is rapid and easy to perform with 
commonly available equipment. Although this research demonstrated the use of 
affinity electrophoresis using the well-established A-site-aminoglycoside and TSMC-
aminoglycoside interactions, this method should be applicable for gauging the 
binding of any RNA molecule to any small molecule embedded in a gel and for 
screening the potential binding of RNA molecules of different sequences and 
structures to known RNA ligands. 
Furthermore, this research has shown that an affinity electrophoresis based 
method can be made quantifiable for determining dissociation constants of RNA-
aminoglycoside interactions. This method can easily be applied to other RNA-small 
molecules using equipment and reagents common to most laboratories. 
Furthermore, synthesis of other cross-linked aminoglycosides and subsequent 
testing to different RNA molecules with various sequences and sizes can also be 
achieved following our method to obtain quantitative binding information. 
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